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ABSTRACT
Obesity and Type 2 diabetes are associated with high fat diet (HFD), reduced
mitochondrial mass and function and insulin resistance as characterized by glucose
disposal and relative to body fatness.
We hypothesized that (a) HFD affects expression of genes involved in
mitochondrial biogenesis and function, (b) carbohydrate metabolism and storage is under
transcriptional control and (c) both overall fatness and characteristics of adipose tissue
influence the interplay between free fatty acids (FFAs) and insulin-stimulated glucose
disposal. To test hypotheses “a” and “b”, we fed 10 insulin-sensitive males an
isoenergetic HFD for 3 days with muscle biopsies before and after intervention.
Oligonucleotide microarrays revealed 370 genes differentially regulated in response to
HFD (Bonferonni adjusted p < 0.001). Expression of six genes involved in oxidative
phosphorylation decreased. PGC1α and PGC1ß mRNAs decreased by ~22%. Seven
genes in the carbohydrate metabolism pathway changed in response to HFD, and three
genes confirmed by qRT-PCR: PFKFB3, PDK4 and GYS1. In a separate experiment,
C57Bl/6J mice were fed HFD for three weeks and the same OXPHOS and PGC1 mRNAs
decreased by ~90%, Cytochrome C and PGC1α protein by ~40%, while the same glucose
metabolism genes changed by ~70%. These results suggest a mechanism whereby HFD
downregulates genes necessary for oxidative phosphorylation and mitochondrial
biogenesis, as well as glucose utilization and storage. These changes mimic those
observed in diabetes and insulin resistance.
To test hypothesis “c”, we measured changes in respiratory quotient (∆RQ;
metabolic flexibility) before and during euglycemic-hyperinsulinemic clamps in healthy

viii

young males. Anthropometric, laboratory measurements, fat biopsies and fat cell size
(FCS) were measured after overnight fast. Adipose tissue gene expression (qRT-PCR)
was measured. Metabolic inflexibility (lower ∆RQ) was associated with higher body fat,
larger FCS and higher insulin-suppressed FFAs. ∆RQ was not related to fasting FFAs,
but lower ∆RQ was associated with lower serum adiponectin levels. Higher adipose
tissue inflammatory gene expression was associated with higher insulin-suppressed FFAs
and lower ∆RQ. These results indicate fatness, adipocyte hypertrophy, blunted insulin
suppression of FFAs, decreased adiponectin levels and inflammation, are associated with
decreased insulin-stimulated glucose uptake and oxidation, an important component of
metabolic inflexibility.
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CHAPTER 1: INTRODUCTION
1.1 Obesity and Diabetes: A Pandemic
An obesity pandemic threatens to overwhelm health systems around the globe with
illnesses such as diabetes and heart disease, and this pandemic of obesity is as big of a threat to
the world’s population as global warming and bird flu. The World Health Organization (WHO)
says more than 1 billion adults are overweight and 300 million of them are obese; furthermore, to
date more overweight people exist in the world than the undernourished, who number about 600
million (1).
Obesity is a major cause of premature mortality with severe economic consequences. A
recent study estimated the annual cost of obesity in the United States to be $93 billion per year,
or 9.1% of all healthcare dollars (2). A recent survey by the United States Centers for Disease
Control indicates that 66% of the U.S. population are overweight, with 32.3% having a body
mass index (BMI) of more than 30 kg/m2 (3).
The current worldwide pandemic of obesity and its major complications, namely Type 2
diabetes and cardiovascular disease (CVD), is well documented. “Thrifty” metabolic traits have
evolved in the setting of decreased famine to give rise to the obesity pandemic. These thrifty
traits, specifically a decreased capacity for dietary thermogenesis and an increased resistance to
insulin-mediated glucose uptake in skeletal muscle, would historically prolong survival during
famine but now predispose individuals to obesity and diabetes in the face of abundance (4-6).
Body-fat distribution is an important factor in determining high-risk obesity. People with
abdominal obesity are at greater risk for heart disease, diabetes, hypertension and hyperlipidemia
compared to people with a more gluteal fat distribution (7). The reason for the association
between central abdominal obesity and metabolic syndrome is not clear, but one leading concept
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maintains that visceral adipose tissue has a higher rate of lipolysis, resulting in elevated portal
non-esterified fatty acids (NEFAs) increasing hepatic very-low-density lipoprotein (VLDL)
production, hepatic glucose output (HGO) and impairing peripheral insulin sensitivity (8).
Considerable evidence exists in the literature for increased inflammation preceding the
onset of obesity-related metabolic disorders. Many studies have described correlations between
vascular disease and elevated levels of interleukin-6, C-reactive protein and chemokines such as
macrophage chemoattractant protein-1 (MCP-1) all of which promote a proinflammatory state
(9). Although the origin of this proinflammatory state is not clear, it is important to note the
commonalities among the development of obesity and certain features of the metabolic
syndrome, such as insulin resistance and vascular disease. All of these suggest that adipose
tissue itself may be an important source of proinflammatory cytokines.
The role of adipose tissue in metabolic syndrome and inflammation has continued to
evolve with the discoveries of numerous secretory proteins from adipocytes, commonly referred
to as adipokines. These adipokines are important determinants of insulin resistance, either
through a hormonal effect in the circulation, or through local effects on the adipocytes
themselves. Tumor necrosis factor-α (TNFα) expression by adipose tissue of obese rodents and
humans was discovered in the mid-1990s (10; 11). Numerous other proteins are secreted by
adipocytes, showing adipose tissue is an active metabolic and endocrine tissue. Many of the
numerous adipokines expressed by adipose tissue have been implicated in the pathogenesis of
metabolic syndrome. For example, plasma levels of interleukin-6 and adipose-secreted TNFα
are associated with obesity, as well as with insulin resistance not related to obesity (12). Several
mechanisms exist for the actions of TNFα on insulin resistance, including an inhibition of
insulin-receptor signaling (13), along with an autocrine effect on adipose tissue causing a
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stimulation of lipolysis and elevation of plasma NEFAs (14). Consistent with this model, TNFαknockout mice do not become insulin resistant with diet-induced obesity (15).
Another important secretory protein of the adipocytes is adiponectin. Unlike other
adipokines, adiponectin acts as an anti-diabetic hormone (16). Adiponectin circulates as
complex multimeric forms (17), and two receptors for adiponectin have been described (18).
Adiponectin-knockout mice develop marked insulin resistance while consuming high-fat diets,
and this insulin resistance is improved following adiponectin supplementation (19). In humans,
blood levels of adiponectin are decreased under conditions of obesity, insulin resistance, Type 2
diabetes and coronary disease (20; 21).
Recent studies, however, have suggested that the cell producing many of the adipose
tissue cytokines is not the adipocyte, but instead is the macrophage that infiltrates adipose tissue
during obesity (22; 23). Once activated, macrophages secrete a plethora of cytokines such as
TNFα, interleukin-6 and interleukin-1 (24), and the adipose tissue resident macrophages were
found to be responsible for the expression of most of the tissue TNFα and interleukin-6 (25; 26).
In human studies, there is a correlation between adipose macrophage markers and BMI (22), and
an even stronger relationship with insulin resistance. The expression of TNFα and interleukin-6
correlate strongly with the expression of macrophage markers from adipose tissue (27). These
adipose-tissue macrophages elucidate our understanding of inflammation, obesity and the
metabolic syndrome. Recent data suggest that progressive obesity leads to adipose-tissue
macrophage infiltration, at least in some subjects, with consequent over-expression of
inflammatory cytokines, metabolic syndrome and a state of heightened inflammation (24; 28).
The prevalence of obesity is increasing at an alarming rate, and the obesity pandemic is
driving the pandemic of Type 2 diabetes. High-risk obesity is characterized by abdominal
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obesity with abnormal glucose and lipid metabolism, and a state of increased inflammation. As
body weight increases, lipid accumulation occurs in adipose tissue, as well as in other organs, the
latter effect commonly referred to as ‘lipotoxicity’. Lipotoxicity in liver, muscle and the
pancreatic islets may account for many of the features of the metabolic syndrome.
Consequently, it may be a culmination of the effects of all four tissues (pancreatic β-cells, liver,
adipose tissue and skeletal muscle) that leads to the state of insulin resistance and ultimately
overt Type 2 diabetes.
Adipose tissue is the primary organ of lipid storage; however, in the case of obesity, lipid
is deposited into other non-adipose organs, including liver, skeletal muscle, β-cells and cardiac
tissue, leading to ‘ectopic fat’. The ectopic fat deposited in the liver leads to the commonly
observed hepatic steatosis, also known as non-alcoholic steatohepatitis or “fatty liver”.
Together, the lipotoxicity in these organs leads to insulin resistance, impaired insulin secretion
and eventually Type 2 diabetes. Because the majority of glucose disposal occurs in muscle (29),
this tissue is extremely important in understanding the mechanisms underlying peripheral insulin
resistance. Insulin-resistant subjects demonstrate increased intramyocellular lipid, a decreased
proportion of the oxidative type I and type IIA muscle fibers, decreased oxidative capacity of
each class of muscle fiber and decreased capillary density (30; 31). Recent studies that compared
insulin-resistant and insulin-sensitive subjects have suggested the presence of a reduced
mitochondrial lipid oxidation as an early defect (32; 33). Improvement in the intramyocellular
lipid and muscle lipid oxidative capacity accompanies improvement in insulin resistance
following weight loss (34), and in response to treatment of insulin-resistant subjects with
pioglitazone, which causes a shift in lipid from ectopic sites to subcutaneous adipose tissue (35).
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A reduction, therefore, in intramyocellular lipid flux or an increased sequestation of lipid in
adipose tissue may be an attractive target for future drug therapies.
Indeed, muscle impairments in insulin-mediated glucose transport, glycogen synthesis
and glucose oxidative pathways are the central features of individuals at high risk for Type 2
diabetes, such as the offspring of Type 2 diabetics (36; 37). As these population groups also
present with elevated plasma concentrations of fatty acids and amino acids, these substrates (by
interfering with the uptake and metabolism of glucose in skeletal muscle) are thought to play a
central role in the onset of insulin resistance (36; 38-40). Furthermore, there is also evidence that
as chronic hyperglycemia develops, the oversupply of glucose could also, by inhibiting fatty acid
oxidation, lead to the accumulation of intramyocellular lipid that further inhibits glucose uptake
and subsequent metabolism and hence exacerbates the state of insulin resistance (e.g. the
‘reverse Randle Cycle’) (41-43).
The complications of obesity affect all specialties of medicine, and the effective
treatment of obesity will be one of the major challenges for the 21st century. Until effective
medical therapy becomes available, it is important to identify patients with evidence of the
metabolic syndrome and other features of high-risk obesity and to treat the diabetes,
hyperlipidemia, inflammation and other associated co-morbidities effectively.
The treatment of obesity requires the identification of the high-risk patient, the institution
of lifestyle measures with a long-term outlook and an avoidance of extreme fad diets. Current
research will likely lead to improved medications in the future.
1.2 Substrate Utilization
Substrates compete for respiration. Beginning in the 1930s Krebs (44) showed
competition between amino acids and glucose in kidney slices. Subsequent to Krebs, Waters et
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al demonstrated a competition between 3-hydroxybutyrate and glucose in dog heart lung
preparations (45). However, general acceptance of the concept came in 1963 with Sir Randle’s
demonstration that lipid fuels inhibit glucose oxidation in rat diaphragm and perfused heart (46;
47). This lead to Randle et al (48; 49) proposing a ‘glucose-fatty acid cycle’ as an important set
of mechanisms by which carbohydrate and fat metabolism interact. As recently as 1998, Randle
revisited the essential components of this cycle (50): (1) the relationship between glucose and
fatty acid oxidation is reciprocal and not dependent, (2) in vivo, the oxidation of lipid fuels (fatty
acids and ketone bodies) released into the circulation (e.g., in starvation or diabetes) may inhibit
the catabolism of glucose in muscle and (3) in vitro, the oxidation of fatty acids released from
muscle triacylglycerol or intramyocellular triglycerides also inhibits intracellular glucose
metabolism.
Frayn reevaluated the ‘glucose-fatty acid cycle’ from a physiological perspective and
pointed out that it is appropriately termed a ‘cycle’ because it describes a series of events that
interlink carbohydrate and fat metabolism (51). Elevated glucose concentrations (as in the postprandial state after a meal) stimulate insulin secretion, which then suppresses free fatty acid
(FFA) release from adipose tissue. This eliminates competition for substrate utilization in
skeletal muscle, so that glucose utilization may be stimulated by insulin, unaffected by high
concentrations of fatty acids. Conversely, when plasma FFAs are high, which is usually because
glucose and insulin concentrations are low (as in the post-absorptive state), fatty acids then
become the major fuel for skeletal muscle. According to Frayn, “This makes perfect
physiological sense in terms of blood glucose homeostasis. The ‘coarse’ control of the
reciprocal utilization of glucose and FFA in the body is brought about through insulin secretion:
fine-tuning is provided in skeletal muscle” (51).
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The Randle (glucose-fatty acid) Cycle embodies the concept of direct competition
between substrates for mitochondrial oxidation. A plethora of mechanisms have been put
forward concerning the biochemical regulation of fuel homeostasis in skeletal muscle (40; 41).
Interestingly, the oversupply of each of the three main fuel substrates (fatty acids, amino acids,
glucose) converges towards the accumulation of triglycerides. This can occur when circulating
free fatty acids (FFAs) exceed FFA oxidation, as well as when amino acids from protein or
glucose from carbohydrate exceed their oxidation; malonyl-CoA is formed in each case driving
lipid synthesis (52). Malonyl-CoA inhibits carnitine palmitoyltransferase-1 (CPT-1), which
reduces entry of long-chain fatty acyl-CoAs into mitochondrial fatty acid oxidation. The
consequence of this excess unoxidized lipid leads to an effect known as ‘lipotoxicity’, which can
lead to the development of intramuscular lipid droplets. Intramuscular lipid impairs insulin
signaling, which is necessary for insulin-stimulated glucose uptake and consequently glucose
metabolism. Lipotoxicity can also lead to ceramide synthesis and lipid peroxidation via
nonoxidative metabolic pathways, leading to cell dysfunction and death through apoptosis (53).
The term ‘lipotoxicity’ indicates toxicity that may result from lipid overloading induced
by delivery exceeding oxidation of circulating FFA and local release of FFAs from triglyceride
stores by lipoprotein lipase (LPL), but also from that induced by glucose overloading (glucolipotoxicity) and protein overloading (or proteo-lipotoxicity). These models of lipotoxicity
explain how nutrient supply exceeding oxidation may lead to insulin resistance in skeletal
muscle. In addition, fuel oxidation matches increased fuel supply vis-à-vis cellular nutrient
sensors and signaling systems, and contributes to blood glucose homeostasis and protection
against muscle lipotoxicity. Tthe interactions between glucose and lipid metabolism in skeletal
muscle in relation to blood glucose homeostasis, and subsequently these interactions with respect
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to thermogenic mechanism of substrate cycling could offer protection against skeletal muscle
lipotoxicity.
The inhibitory effect of elevated lipid fuels (fatty acids and ketone bodies) on glucose
disposal in skeletal muscle has been established by numerous studies conducted both in vivo and
in vitro. In humans, it has been shown that under in vivo conditions when fatty acid
concentrations are elevated (e.g., in response to lipid infusion) whole body, as well as skeletal
muscle glucose utilization, is impaired (54-56). The plethora of mechanisms put forward to
explain how fatty acids limit insulin-stimulated glucose utilization fall into two main categories.
Both categories were first proposed by Randle following the original studies which formed the
basis of the ‘glucose-fatty acid cycle’: (1) fatty acid-induced desensitization of insulin-mediated
glucose transport and (2) inhibitory effects of fatty acid oxidation (46-49). According to Randle,
an increase in lipid oxidation will decrease glucose oxidation by suppression of the
mitochondrial pyruvate dehydrogenase (PDH) complex, with the subsequent reduction of
glycolytic flux, which results in an increase in glucose-6-phosphate, inhibition of hexokinase
activity and ultimately decreased glucose uptake. As a result of this, nonoxidative metabolism
(storage) of glucose should decrease. A variety of model systems have largely confirmed the
validity of Randle’s mechanism, at least in terms of the acute effects of fatty acids on muscle
glucose metabolism and storage (50; 57).
In the late 1970s McGarry et al elucidated the reciprocal nature of interactions between
glucose and lipid metabolism by demonstrating that high glucose (and insulin) concentrations
can suppress hepatic fatty acid oxidation through malonyl-CoA inhibition of CPT-1, a key ratelimiting enzyme that controls the entry of fatty acids into the mitochondrial fatty acid oxidation
system (58; 59). This mechanism by which glucose regulates fatty acid oxidation is
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complementary to the mechanism described by Randle et al and is often referred to as the
‘reverse glucose-fatty acid cycle’. Malonyl-CoA inhibition of fatty acid oxidation contributes to
the switch to pyruvate oxidation; however, inhibition of acetyl-CoA carboxylase (ACC), which
produces malonyl-CoA from acetyl-CoA, enables fatty acid oxidation at the expense of glucose
oxidation. This ‘reverse glucose-fatty acid cycle’ can be viewed as further ‘fine-tuning’ of the
balance between glucose and fatty acid metabolism, and it adds weight to the bi-directionality of
the cycle.
Recently, a new twist and important question was posed regarding glucose inhibition of
fatty acid oxidation, namely: “How can one substrate have opposing roles?” Mitochondrial fatty
acid oxidation is inhibited by an elevation in malonyl-CoA, an intermediate substrate (formed
from acetyl-CoA by ACC) that is also a precursor for de novo fatty acid synthesis--hence, the
paradox (60). The role of malonyl-CoA as a precursor of lipid synthesis and as an inhibitor of
lipid oxidation was eventually reconciled with the discovery of two isoforms of ACC (61; 62).
ACC1 is expressed predominantly in lipogenic tissues that synthesize large amounts of fatty
acids (liver and adipose tissue) and ACC2 is expressed in non-lipogenic tissues such as skeletal
muscle and cardiac muscle. ACC1 is thought to reside in the cytoplasm, where it synthesizes the
pool of malonyl-CoA that is used for de novo lipogenesis; whereas, ACC2 is thought to control
the pool of malonyl-CoA that regulates fatty acid oxidation.
In skeletal muscle, the suppressive effect of elevated glucose on fatty acid oxidation
occurs via malonyl-CoA (synthesized by ACC2) inhibition of CPT-1, but the question of
whether a cytoplasmic pool of malonyl-CoA might be used for fatty acid synthesis has not been
raised. Historically, skeletal muscle is not an organ where de novo lipogenesis occurs.
Whenever the expression or activity of a rate-limiting enzyme for de novo lipogenesis (e.g., fatty
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acid synthase) was reported in skeletal muscle, this was just thought to be adipocyte
contamination rather than de novo lipogenesis occurring in myocytes (52; 63). As a
consequence, the role of skeletal muscle substrate metabolism in blood glucose homeostasis has
been viewed from the relationship between glucose and lipid metabolism. Recent evidence,
however, suggests that skeletal muscle has a more active role. De novo lipogenesis can occur in
muscle cells and be modulated by factors that influence the body’s nutritional state; therefore,
glucose and lipid metabolism may actually depend on, rather than respond to, each other for
these two fuel substrates in skeletal muscle. This is in contrast to Randle’s revisit of the
‘glucose-fatty acid cycle’ in 1998 (50).
It has been proposed that there is an interdependency between glucose, lipids and
thermogenesis. Acetyl-CoA produced from glucose and fatty acid oxidation may overload the
Krebs cycle. This, in turn, results in excess mitochondrial citrate, which activates ACC2 and
also provides substrate (in the form of acetyl-CoA) to ACC2 for the synthesis of malonyl-CoA.
Malonyl-CoA serves as the main substrate for fatty acid synthase (FAS), which produces a new
pool of fatty acids. On the other side of the equation, glucose plays a central role in this cycle as
a source of acetyl-CoA, Krebs cycle intermediates and NADPH molecules, which are required
for fatty acid synthesis. Glucose might also function as a stimulator of de novo lipogenesis,
based on recent evidence in rat muscle satellite cells that glucose stimulates expression of genes
encoding glycolytic and lipogenic enzymes, leading to an increased lipogenic flux (64).
Skeletal muscle adapts to three different physiological conditions by increasing fat
oxidation: (1) reduced energy intake during fasting, (2) increased energy expenditure during
exercise (65) and (3) in obesity (66-68). The transition to fat oxidation for energy spares glucose
metabolism during fasting and delays muscle glycogen metabolism during exercise. Almost 50
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years ago, it was reported that even in lean, healthy volunteers after just an overnight fast,
skeletal muscle chiefly relies upon fat oxidation for fuel supply (69). Recently, it has been
proposed that inability to increase reliance upon fat oxidation is related to the pathogenesis of
insulin resistance in skeletal muscle and perhaps to the pathogenesis of obesity (70; 71). To this
end, Ukropcova et al examined the capacity for fat oxidation in skeletal muscle by using primary
human skeletal muscle cells obtained from biopsy of the vastus lateralis. They found that fatty
acid oxidation was increased in cells from subjects with higher insulin sensitivity, leanness and
aerobic fitness (72).
The physiologic purpose of alterations in fuel selection is to channel energy to and from
the appropriate storage compartments under all circumstances that may confront the organism.
An obligate need exists to regulate glycogen within a relatively narrow window. Studies
conducted in subjects with Type 2 diabetes and in healthy subjects to determine the fate of
glucose after it is taken up by muscle cells demonstrate that muscle glycogen synthesis, along
with glycolysis, is an important pathway in overall skeletal muscle glucose metabolism (76).
Muscle cells adjust the fuels they oxidize in order to match substrate supply, signals from the
endocrine and neural systems and the ATP required for contraction. The supply of substrate to
muscle tissue depends upon several factors including the dietary macronutrient content, the
storage of nutrients in liver and fat, capillary recruitment and transport, and in the case of
triglycerides, the release of free fatty acids by the enzymatic activity of lipoprotein lipase (LPL) at
the surface of the cell. The adjustment of substrate oxidation to the local nutrient concentrations
occurs through at least three mechanisms: minute-to-minute changes in the activity of enzymes
that direct carbohydrate and fat into oxidation or storage (86), the activation of signaling
pathways such as PKC (98) and NFκB (190) and through long-term regulatory systems that
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involve changes in gene transcription and hence the cellular machinery driving the first two
processes. The ability of insulin to regulate glucose homeostasis, i.e. insulin sensitivity, is
closely related to these regulatory pathways, justifying further attempts to unravel the details of
these regulatory systems. Strong experimental evidence exists for each of these pathways,
particularly for the regulation of substrate utilization and insulin sensitivity through enzyme
activity (87) and signaling pathways (98).
Skeletal muscle plays a key role in determining systemic insulin sensitivity. Upon insulin
stimulation the majority of glucose metabolism occurs in the skeletal muscle. Impaired glucose
metabolism in muscle constitutes peripheral insulin resistance and is seen in Type 2 diabetes and
obesity. Is the impairment of skeletal muscle to increase fat oxidation under appropriate
conditions also related to insulin resistance? Insulin resistance in muscle can be induced by
elevated plasma fatty acids levels. High FFAs are also associated with increased fat oxidation
(54; 57). Maintenance of fasting levels of plasma fatty acids through lipid infusions significantly
lowers insulin-stimulated glucose uptake by skeletal muscle, impairs insulin suppression of lipid
oxidation and blunts stimulation of glucose oxidation in muscle (56). These experimental
conditions, which induce insulin resistance in skeletal muscle by elevating circulating free fatty
acids, mimic those found in obesity and Type 2 diabetes (73; 74). These observations
complicate the evidence that insulin-resistant skeletal muscle can also demonstrate reduced
efficiency of fat oxidation during fasting despite high levels of plasma free fatty acids, which are
almost invariably present in obesity and Type 2 diabetes, as well as high very low density
lipoprotein (VLDL) triglycerides and intermediate density lipoprotein (IDL) triglycerides.
Kelley et al showed a high reliance of leg muscle on fat oxidation (lower RQ) during
fasting conditions. In these same individuals, insulin infusion suppressed fat oxidation and
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shifted to a high reliance on glucose oxidation (higher RQ) (75); therefore, metabolically healthy
skeletal muscle is characterized by the ability to switch easily between glucose and fat oxidation
in response to homeostatic signals and substrate availability. The skeletal muscle of individuals
with Type 2 diabetes (T2D) and obesity demonstrates decreased metabolic flexibility. Even
though RQ values during fasting are higher in T2D and obesity, stimulation of glucose oxidation
in response to insulin is blunted (76; 77). This phenomenon of responding inefficiently both to
the fasting stimulus to enhance fat oxidation and to the insulin stimulus to turn on glucose
oxidation has been termed “metabolic inflexibility”. Ukropcova et al examined metabolic
flexibility in their cultured myocytes (72) and found a match between the cellular characteristics
and the whole body “metabolic flexibility” of the cellular donor. Furthermore, Goodpaster et al
found that moderate weight loss, combined with an improvement in aerobic capacity, can restore
metabolic flexibility and improve insulin-stimulated glucose disposal in overweight and obese
insulin-resistant individuals (78). Interestingly, however, moderate weight loss without a change
in aerobic capacity does not improve fat oxidation under fasting conditions, rather it improves
suppression of fat oxidation during insulin-stimulated conditions (79; 80).
Metabolic flexibility involves: (1) insulin suppression of fat oxidation with stimulation
of glucose oxidation, and (2) stimulation of fat oxidation during fasting. In the study by
Ukropcova et al, glucose had a varying effect on the suppression of fat oxidation in the primary
human myocytes. Resistance to suppression of fat oxidation by hyperglycemia was inversely
related to insulin sensitivity, percent body fat and aerobic capacity (72).
Another study by Henry et al found that characteristics of insulin resistance in skeletal
muscle are retained in myocyte culture (81), and it has been reported that muscle obtained from
Type 2 diabetics has reduced capacity for fat oxidation in culture (82). Additionally, the results
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reported by Ukropcova et al demonstrate metabolic flexibility (the transition between fat and
glucose oxidation) is a cellular characteristic that is retained in vitro. It is not clear what the
cellular characteristics of myocytes determine metabolic flexibility, but Ukropcova et al did show
that mitochondria play a critical role. Competition between glucose and fat oxidation can occur
at several locations in the mitochondria. One location is the mitochondrial outer membrane
where pyruvate dehydrogenase and carnitine palmitoyl transferase complexes compete for
acetyl-CoA. Competition may also occur in the mitochondrial matrix between β-oxidation (fatty
acid oxidation) and the tricarboxylic acid (TCA) cycle, as well as in the delivery of FADH2 and
NADH molecules to the electron transport chain (ETC) for oxidative phosphorylation in the
inner mitochondrial membrane.
Recently, mitochondria have become a hot topic in the investigation of the pathogenesis
of muscle insulin resistance (83-87). In addition to clinical investigations, suitable animal
models for further study are also being developed. For example, rats selectively bred for low
oxidative enzyme activity in skeletal muscle develop a metabolic syndrome phenotype (88).
Also, in studies that examined the physiological phenotype of metabolic flexibility, muscle
biopsy samples have shown reduced oxidative enzyme activity (33; 80; 89).
In the future it will be important to examine the links between substrate utilization and
mitochondrial metabolism and incorporate the findings into the broader spectrum of metabolic
pathways within insulin-sensitive tissues, such as liver, adipose tissue and skeletal muscle.
Understanding metabolic adaptation to our nutritional environment is important to the future of
obesity and diabetes research.
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1.3 The ADAPT Study Design
The ADAPT study began in 2000 and completed in 2003. In the past several years a
“thrifty phenotype” has been identified and characterized in lean men by Smith et al as an
inability to adapt rapidly to a high fat diet by increasing fatty acid oxidation. It is associated with
a low maximal VO2 during exercise and a high fasting insulin. We hypothesized that individuals
with the “thrifty phenotype” are at higher risk for becoming obese, and that exercise may be
effective in overcoming this problem. The latter hypothesis was supported as treadmill exercise
increased the rate of adaptation to a high fat diet (90).
Several questions remained to be answered regarding this “thrifty phenotype”. First,
given the large interindividual differences in fatty acid oxidation, how could we identify those
individuals at the highest risk? What would be the distinguishing biochemical, endocrine and
environmental characteristics of individuals that store fat when exposed to high fat diets? This
was important because if these individuals could be easily identified, then dietary and other
interventions could be targeted to this “at-risk” population.
Second, what would be different about the individual with the “thrifty phenotype”? What
would be the cellular pathways dysregulated in the skeletal muscle of these individuals? If the
defect was intrinsic, i.e. a diminished ability to conserve glucose and oxidize fat in skeletal
muscle or alternately, was the phenotype due to environmental, and dietary factors such as
inactivity and energy excess?
To answer these questions we planned a three-year project that aimed to: (1) characterize
the biochemical, endocrine, anthropometric and environmental characteristics of individuals with
the “thrifty phenotype”, (2) identify the signaling pathways in skeletal muscle that are
dysregulated in individuals with the “thrifty phenotype” through mRNA expression profiling and
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(3) determine the role of environmental factors such as inactivity and caloric intake versus
intrinsic (genetic) factors in the “thrifty phenotype”.
The first component of the proposed experiment was to compare adaptation to high fat,
versus low carbohydrate diets in men versus women, particularly comparing women with a
central versus peripheral fat distribution pattern. Capacity to adapt to high fat diets was
measured at energy balance in a whole room calorimeter after feeding a high-fat diet on the
preceding three days (see experimental schedule below). In an attempt to sort out the relative
role of these factors in the “thrifty phenotype” we measured: socioeconomic status, body
composition, family history of diabetes and obesity, fat preference, restraint/disinhibition, core
body temperature, habitual physical activity, aerobic capacity, insulin sensitivity, energy related
hormones and sympathetic nervous system (SNS) activity (as measured by heart rate variability
+ plasma and urinary catecholamines). We measured food intake after three days of a high fat
diet to determine if the decrease in carbohydrate stores in “thrifty” individuals would increase
subsequent food intake.
The second component of the proposed experiment was to compare the biochemical and
signaling pathways dysregulated in skeletal muscle and adipose tissue of the individual with the
“thrifty phenotype” compared to “fat-burning individuals”. Before and after the measurement of
their capacity to adapt to high fat diets as described above, individuals with high and low fat
oxidative capacity underwent an adipose tissue and skeletal muscle biopsy. These samples were
examined for gene expression for several candidate genes from pathways involved in substrate
utilization and energy/nutrient sensing
In addition to the candidate gene approach, these samples were analyzed using
microarray resources at Pennington Biomedical Research Center. The expression data was
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analyzed using cluster analysis, gene shaving and other advanced bioinformatics techniques (91102). We confirmed differentially expressed mRNAs and proteins using Western blotting and/or
enzyme assays.
The third component was to determine if the phenotype of impaired fat oxidation was
preserved in vitro. In this study, skeletal muscle from “thrifty” and “non-thrifty” individuals was
cultured in vitro and fat versus carbohydrate oxidation was determined at various concentrations
of insulin. We then compared the phenotype in vitro with the phenotype in vivo. If the
phenotype was retained, then we concluded that the defect was genetic. If the phenotype was not
retained, then we concluded that the defect lie in the neural or endocrine systems or was
environmental. Studies of this type were critical in understanding the role of genetics in the
metabolic disorder of insulin resistance syndrome (81).
All volunteers had to complete a two-stage screening study. Screening visit one was for
blood sampling (chem 16 with lipids, CBC, UA). Screening visit two was for physical
examination and familiarization with the metabolic chamber.
Eligible volunteers were screened and signed a consent document. After enrolling into
the study, the volunteers completed the baseline measures. After consuming the control diet for
one day, they were admitted to the metabolic unit for testing at 6pm. On the next day, baseline
blood samples (GLP-1, leptin, ghrelin, resistin, insulin, C-reactive protein (CRP), C-peptide,
glucose, NEFA, lipids, study archives) were drawn. After local anesthesia, a muscle and a fat
biopsy were performed. The next test was an insulin-glucose clamp to measure insulin
sensitivity and metabolic flexibility.
The next four days were spent in the metabolic chamber: one day with the standard diet
and three days with the high fat diet. Each day, the volunteers exited the chamber, a butterfly IV
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was inserted, they rested in a recumbent condition for 30 minutes and a basal blood sample was
collected. After exiting the chamber on the fourth day, volunteers had the last morning blood
sample drawn and then consumed the test meal.
Both genders and all races were invited to participate. Women were asked to participate
in the follicular phase of the menstrual cycle as determined by menstrual history, and a negative
pregnancy test was also recorded prior to participation. Body mass index (BMI) range was > 19
and < 30. Age range was 18 to 30 years.
Table 1.1 Clinical procedures for the ADAPT study.

procedure

baseline

run-in diet
Su

body composition
exercise test
activity monitor
metabolic cart
questionnaires
insulin clamp
blood draw
metabolic chamber
core temperature
fasting blood sample
heart rate variability
urine collection
biopsy

M
inpatient

high-fat diet
Tu
W
Th
F
metabolic chamber

Sat

X
X
X
X
X
X

X
X

X

X

X

X

X
X
X
X
X
X

X
X
X
X

X
X
X
X

X
X
X
X

X

X

X

X
X
X

Smokers were excluded from the study. Volunteers who were unwilling or unable to
abstain from alcohol consumption and caffeine consumption prior to testing and laboratory were
excluded. Significant renal, hepatic, endocrine, pulmonary, cardiac or hematological diseases
were also exclusionary. Women who were pregnant, post-menopausal or taking oral
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contraceptives or estrogen replacement therapy were excluded. Other exclusion criteria
included: (1) corticosteroid use in the previous two months, (2) chronic use of anti-diabetic,
anti-hypertensive or other medications known to affect fat metabolism and (3) weight gain or
loss > 3kg in the previous six months.
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CHAPTER 2: EXPERIMENTAL PROCEDURES
2.1 Euglycemic-hyperinsulinemic Clamp (EHC)
Insulin sensitivity and metabolic flexibility (change in respiratory quotient (∆RQ) from
fasting to insulin-stimulated) was measured by euglycemic-hyperinsulinemic clamp (103) prior
to HFD. After an overnight fast, insulin [80mIU/m2BSA] was administered intraveneously and
glucose infused to maintain plasma glucose at 90mg/dl for 2 hours. The glucose disposal rate
(GDR; mg/kgFFM/min), was adjusted for kg of lean body mass.
2.2 Maximal Aerobic Capacity (VO2 Max)
Maximal oxygen uptake was determined by a progressive treadmill test to exhaustion
(104). The volumes of O2 (VO2) and CO2 (VCO2) were measured continuously using a metabolic
cart (V-Max29 Series, SensorMedics, Yorba Linda, California).
2.3 Body Composition (DEXA)
Body fat mass and lean body mass were measured on a Hologic Dual Energy X-Ray
Absorptiometer (QDR 2000, Hologic, Inc. Waltham, MA). Visceral fat was measured by CT
scanning using a High SpeedTM CT scanner under an established protocol (105).
2.4 Indirect Calorimetry
24-hour energy expenditure and respiratory quotient (RQ) were determined in the whole
room respiratory calorimeter, prior and during 3 days of isocaloric high fat diet. Energy
expenditure was set at 1.4 times the resting metabolic rate and clamped across the 4-day chamber
stay. After an overnight fast, fasting and steady state (insulin infusion) respiratory quotient (RQ)
were measured for 20 minutes by indirect calorimetry during the EHC using a Deltratrac II
indirect calorimeter (DATEX-Ohmeda, Helsinki, Finland). Oxidative and non-oxidative glucose
disposal was calculated as described by Livesy (106).
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2.5 Laboratory Measures
Baseline serum glucose and free fatty acids were assayed by established enzymatic
procedures (Beckman Synchron CX7 or CX5; Beckman Coulter, Brea, CA) using the Wako FFA
reagents (Richmond, VA). Baseline plasma insulin and C-peptide were measured on an
Immulite autoanalyzer (DPC, Los Angeles, CA). Steady state (insulin infusion) serum glucose
and insulin were assayed during the euglycemic-hyperinsulinemic clamp in the same manner as
the baseline samples. The enzymatic assay was not sensitive enough to reliably measure insulinsuppressed free fatty acids (FFAs), so steady state (insulin infusion) FFAs were measured in
triplicate by high performance liquid chromatography (HPLC) as previously described (107) by
Dr. John Miles, Mayo Clinic, Rochester, MN.
2.6 Fat Cell Size
Fat cell size was determined as previously described (108). Briefly, adipose tissue was
fixed in osmium tetrachloride/collidine-HCl followed by disassociation by urea digestion. Cells
were sized and counted on a Multisizer-3 (Beckman Coulter, Fullerton, CA) using a 400-µm
aperture (dynamic linear range, 12–320 µm) and reported as the mean of all adipocytes
>22.5µm.
2.7 Animal Study
Male C57BL/6J mice were housed at room temperature with a 12h light-12h dark cycle
for five weeks. Six mice ate the control diet 10% fat diet (Research Diets, Inc., D12450B, New
Brunswick, NJ: 10% of energy from fat, 20% of energy from protein, 70% of energy from
carbohydrate) and seven mice ate the 45% high fat diet (HFD) (Research Diets, Inc., D12451,
New Brunswick, NJ: 45% of energy from fat, 20% of energy from protein, 35% of energy from
carbohydrate). All animals ate the control diet ad lib for two weeks and then seven were
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switched to the HFD for three additional weeks. The gastrocnemius muscles were dissected and
snap-frozen in liquid nitrogen.
2.8 Preparation of RNA and DNA
Human and mouse total RNA from 50-100 mg vastus lateralis and gastrocnemius muscle,
respectively, was isolated with Trizol reagent (Invitrogen, Carlsbad, CA). Mouse muscle from
20-30 mg gastrocnemius was digested overnight in proteinase K (FisherBiotech, Houston, TX) at
55oC. DNA was extracted the following day with phenol-chloroform. The quantity and the
integrity of the RNA and DNA were confirmed by Agilent 2100 Bioanalyzer according to
manufacturer’s procedure (Agilent Technologies, Palo Alto, CA).
2.9 Preparation of Whole Cell Extracts
Murine muscle tissues were homogenized in buffer (50mM HEPES, pH 7.4, 2mM
EDTA, 150mM NaCl, 30mM NaPPO4, 10mM NaF, 1% Triton X-100, 10µL/mL protease
inhibitor, 10µL/mL phosphatase I inhibitor, 10µL/mL phosphatase II inhibitor, and 1.5mg/mL
benzamidine HCl). The whole homogenates were centrifuged for 25 minutes at 15,000g, and
supernatants were stored at -80 °C prior to Western immunoblotting.
2.10

Oligonucleotide Microarrays
RNA sample pairs (2µg) from the ten subjects were labeled by reverse transcriptase with

dCTP-Cy3 and dCTP-Cy5, respectively, and in the inverse order (dye swap) using MICROMAX
TSA Labeling & Detection kit (Perkin-Elmer, Wellesley, MA). Equal amounts of labeled cDNA
probes were hybridized in duplicate to oligonucleotide slides containing 18,861 spots
corresponding to 17,260 unique oligonucleotides (Compugen, NJ) in hybridization chambers
(GenomicSolutions, Ann Arbor, MI) for up to 72 hours at 42°C. Detection and washing were
performed at room temperature according to manufacturer’s protocol (Perkin-Elmer, Wellesley,
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MA). Oligonucleotide chips were spotted on to poly-L-lysine slides using a GeneMachine
OmniGrid microarrayer (GenomicSolutions, Ann Arbor, MI) equipped with a Stealth SPH32
printhead and Stealth SMP4 Micro Spotting Pins (Telechem Internation, Inc., Sunnyvale, CA).
Oligonucleotides were stored in 384-well plates in 45% DMSO. Microarray slides were scanned
using a GSI Lumonics ScanArray 5000 scanner (Perkin-Elmer, Wellesley, MA) at high
intensities (~95% for Cy3, ~75% for Cy5) and low intensities (~55% for Cy3, ~35% for Cy5)
applying ScanArray Express software and quantified using QuantArray (GenomicSolutions, Ann
Arbor, MI). All subsequent microarray analyses were performed using SAS version 8.2 (SAS,
Cary, NC). A robust local regression procedure (LOWESS) was performed to remove the
systematic variations in the measured gene expression levels so that differences in expression
across the samples could be distinguished accurately and precisely (109). After normalization,
gene shaving (110) and bootstrapping (111), cluster analysis was performed (112), and the slide
effect, dye effect and variety effect, as well as the duplicate design, were taken into account in an
ANOVA model (113). Resampling-based multiple pairwise comparison was used to identify the
differentially expressed genes before versus after the high fat diet. Differentially expressed
genes were identified based on a Bonferroni
adjusted p-value < 0.001.
2.11

Real Time qRT-PCR for RNA
RNA sample pairs (1µg) were reverse transcribed using iScript cDNA synthesis kit

(BioRad, Hercules, CA) and SYBR Green I qRT-PCR (Applied Biosystems, Roche, Branchburg,
NJ). All primers and probes were designed using Primer Express version 2.1 (Applied
Biosystems, Roche, Branchburg, NJ). The sequences of primers and probes and accession
numbers for each gene are shown in Appendix A.1 and Appendix A.3. Real time RT-PCR
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reactions (114) for tested genes were performed using the Taqman technique (Applied
Biosystems, Roche, Branchburg, NJ). Real-time RT-PCRs were performed as one-step reactions
in an ABI PRISM 7900 (Applied, Biosystems, Branchburg, NJ) using the following parameters:
one cycle of 48oC for 30 min, then 95o C for 10 min, followed by 40 cycles at 95oC for 15 sec
and 60oC for 1 min. For all assays performed using SYBR Green I, 18S was used as the internal
control, and for all assays performed using Taqman primers and probe, RPLP0, which is the
human equivalent of the murine 36B4 (115), was used as the internal control. Cyclophilin B was
used for all murine assays. All expression data were normalized by dividing the amount of target
gene by the amount housekeeping gene used as an internal control.
2.12

Real Time qPCR for mtDNA and Genomic DNA Copy Number
Taqman primers and probes were designed using Primer Express version 2.1 (Applied

Biosystems, Roche, Branchburg, NJ). The sequences of primers and probes and accession
numbers for each gene are shown in Appendix A.1. Real-time PCR was carried out in an ABI
PRISM 7900 sequence detector (Applied, Biosystems, Branchburg, NJ) using the following
parameters: one cycle of 50oC for 2 min, then 95o C for 10 min, followed by 40 cycles at 95oC
for 15 sec and 60oC for 1 min. Murine skeletal muscle genomic DNA copy number was
measured at the UCP2 gene using a primer-probe set that amplifies genomic DNA.
Mitochondrial DNA copy number was measured from the COXII mtDNA gene. Mitochondrial
DNA copy number was calculated by first taking the absolute value of the delta Ct values
between groups (control vs. HFD). Because amplification occurs exponentially (increasing twofold with each cycle of PCR), log base 2 of delta Ct as the copy number for each sample (116).
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2.13

Western Immunoblotting
Homogenates were run on a 10% PAGE, transferred to PDVF membranes, incubated

with the primary antibodies PGC1α (#P3363, US Biological, Swampscott, MA) and Cytochrome
C (#556433, BD Biosciences, San Jose, CA) and signal detected using the ECL detection system
(Pierce, Rockford, IL). GAPDH (#4699-9555, Biogenesis, Kingston, NH) was used as an
internal control and brown adipose tissue as positive control.
2.14

Skeletal Muscle Enzyme Activities
Skeletal muscle samples were diluted 20-fold and homogenized in extraction buffer (0.1

M KH2PO4/Na2PHO4, 2 mM EDTA, pH = 7.2). Citrate synthase (CS), Cytochrome C oxidase
(COX) and beta-hydroxyacyl-CoA dehydrogenase (BHAD) activities were determined
spectrophotometrically as previously described (117; 118). DNA was extracted from the same
homogenate (total nucleic acid extraction, Epicentre, Madison, WI) and mtDNA measured to
correct for differences in the content of mitochondria (119).
2.15

Statistical Analysis
Statistical analysis for all real time qRT-PCR and qPCR data in skeletal muscle was

performed using two-tailed paired Student’s t-test for before versus after HFD (human) and
unpaired Student’s t-test for low fat versus high fat diet (mouse) to establish main effects of the
high fat diet intervention. Adipose tissue gene expression and clinical data were correlated using
regressions. The change in respiratory quotient (∆RQ) was divided into quartiles (quartile 1 =
∆RQ < 0.06; quartile 2 = 0.06 < ∆RQ < 0.08; quartile 3 = 0.08 < ∆RQ < 0.11; quartile 4 = ∆RQ
> 0.11) to illustrate the range in metabolic flexibility within the cohort. ANOVA was used to
test for differences in biopsy and blood parameters across quartiles of metabolic flexibility
(∆RQ), with post-hoc testing by mean equality contrast between different groups using the
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Tukey-Kramer HSD; alpha = 0.05. Type I error rate was set a priori at p < 0.05.Analysis was
performed using GraphPad Prism version 4.0 (GraphPad Software Inc., San Diego, CA) and
JMP version 5.0 (SAS, Cary, NC).
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CHAPTER 3: HIGH-FAT DIET DOWNREGULATES OXPHOS GENES*
3.1 Introduction
Type 2 diabetes affects over 110 million people worldwide, and Type 2 diabetes
associated with obesity is reaching epidemic proportions (120; 121). Many pathophysiological
processes have been implicated in diabetes, such as pancreatic β cell dysfunction and defects in
insulin signaling, carbohydrate utilization and mitochondrial metabolism (83; 122). At the
molecular and structural level, mitochondrial biogenesis and mitochondrial function are altered
in diabetes, as well as in insulin-resistant relatives of Type 2 diabetics (86; 123). At the ultrastructural level, a reduction in the number, location and morphology of mitochondria is strongly
associated with insulin resistance (123). Two recent microarray studies have shown that genes
involved in oxidative phosphorylation (OXPHOS) exhibit reduced expression levels in the
skeletal muscle of Type 2 diabetics and prediabetics. These changes may be mediated by the
peroxisome proliferator-activated receptor γ coactivator-1 (PGC1) pathway. PGC1α- and
PGC1β-responsive OXPHOS genes show reduced expression in the muscle of patients with
Type 2 diabetes (83; 84). In addition to the cellular energy sensor AMPK, the peroxisome
proliferator-activated receptor (PPAR) cofactors PGC1α (124-126) and possibly PGC1ß (127)
activate mitochondrial biogenesis and increase OXPHOS gene expression by increasing the
transcription, translation and activation of the transcription factors necessary for mitochondrial
DNA (mtDNA) replication. Similarly, PGC1α increases the transcription of enzymes necessary
for substrate oxidation, electron transport and ATP synthesis. Morphological and functional

* published as Diabetes 54: 1926-1933, 2005, with permission from Diabetes.
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studies (85; 123; 128), combined with the recent microarray data, indicate that PGC1 is
important in the development of Type 2 diabetes.
Rates of ATP synthesis, measured in situ with magnetic resonance spectroscopy, are
decreased in subjects with a family history of diabetes before the onset of impaired glucose
tolerance (85; 86). Based on these results, the prevailing view is that these defects have a genetic
origin (86). One common feature of diverse insulin resistant states is an elevation in nonesterified fatty acids (129). This gave rise to the concept of ‘lipotoxicity’ and ‘ectopic fat’ (130)
and shifted attention toward the adipose tissue and increased free fatty acid concentrations as a
potential foundation for insulin resistance (129).
Excess dietary fat has been implicated in the development of obesity and diabetes (131).
Even at energy balance high fat diets will increase the flux of fatty acids through skeletal muscle
for oxidation. The purpose of these experiments was to identify the transcriptional responses in
skeletal muscle to an in vivo isoenergetic high fat diet (HFD) in healthy young men using
oligonucleotide microarrays. We found downregulation of genes encoding proteins in complex I
and complex II of the electron transport chain after an acute isoenergetic high fat diet. Similarly,
Cytochrome C (complex III protein) and Surfeit 1 (complex IV protein), PGC1α and PGC1β
mRNA were also downregulated by the HFD. These changes were recapitulated and amplified
in a murine model after a three-week HFD. These studies implicate increased fatty acid flux in
the defects in OXPHOS genes observed in diabetes and the prediabetic/insulin-resistant state.
3.2 Results
The characteristics of the study population are presented in Table 3.1. Fasting
glucose, insulin and free fatty acids were unchanged as the diet was switched from a
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‘standard’ fat content (35%) to a high fat diet (50%) (Table 3.2). Intra-subject changes in
skeletal muscle gene expression before vs. after three days eating a 50% high fat diet were
Table 3.1 Characteristics of the study population before the high-fat diet. Ten male subjects
were chosen from the larger study population based on a high aerobic capacity and insulin
sensitivity. BMI, body mass index; GDR, glucose disposal rate; FFA, free fatty acids; FCS, fat
cell size.
Subject Characteristics
Age (y)
Height (cm)
Weight (kg)
BMI (kg/m²)
VO2max (ml/kg/min)
WHR (au)
RQ (au)
Fasting Glucose (ml/dl)
Fasting Insulin (µl/ml)
GDR (mg/kgFFM/min)
FFA (mmol)
Body Fat (%)
FCS (µl)

Mean ± SD
23.0 ± 3.1
179.7 ± 6.3
78.9 ± 13.2
24.3 ± 3.0
48.8 ± 3.3
0.88 ± 0.1
0.87 ± 0.1
78.4 ± 4.7
4.6 ± 1.4
14.7 ± 4.1
0.4 ± 0.1
16.2 ± 3.2
0.93 ± 0.2

Table 3.2 Change in overnight fasting blood parameters after a 50% high fat diet at energy
balance and fixed activity level. Values are presented as sample means + SEM. BL = baseline,
HFD = high fat diet (50%fat). Repeated measures ANOVA was used to test for time effects; P =
0.847, 0.130, 0.047 for glucose, insulin and FFA, respectively. When post-hoc comparisons of
each HFD day vs. average of the two baseline values were significant (p < 0.05; Dunnetts
adjustment) these values are marked with an asterisk.

Variable
Glucose (mg/dl)
Insulin (mIU/ml)
FFAs (mmol)

BL1
88.60 ± 7.38
6.81 ± 3.02
0.26 ± 0.08

BL2
89.77 ± 8.74
6.98 ± 2.86
0.28 ± 0.10

HFD day 1
89.00 ± 9.76
6.65 ± 3.00
0.22 ± 0.08

HFD day 2
HFD day 3
89.40 ± 7.29
90.40 ± 9.03
6.07 ± 2.98 * 6.89 ± 2.67
0.25 ± 0.08
0.27 ± 0.10

identified using oligonucleotide microarrays and analyzed by sequential analysis that included
LOWESS normalization, gene shaving, bootstrapping and ANOVA. A cluster analysis grouped
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the regulated genes into five clusters based on three principal components (Figure 3.1). The
three-day isoenergetic high fat diet significantly changed the expression of 298 genes
0.00
0.00

R2

0.25
0.25

0.50
0.50
0.75
0.75

1.00
1.00

1
1

2
2

3
3
genes
genes

4
4

5
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Figure 3.1 Cluster analysis of changes in gene expression with high-fat diet. In a cohort of
healthy insulin-sensitive males (n=10), effect of a three-day isoenergetic high-fat diet (50% fat
vs. 35% fat) reduced the expression of 298 genes in skeletal muscle. The 298 microarray ‘hits’
are divided among five clusters of co-regulated genes. Clustering was performed using the kmeans technique. Differentially expressed genes were identified based on a Bonferroni adjusted
p-value <0.001. The majority of the oxidative phosphorylation genes ‘hits’ were in cluster # 5.
(p < 0.001; Appendix A.2). 163 genes were upregulated and 135 were downregulated by the
high fat diet. Of those genes, six were known to be involved in oxidative phosphorylation by
visual inspection or through gene ontogeny analysis (p < 0.001; Table 3.3). All of the oxidative
phosphorylation genes were downregulated and none were upregulated. Three of these genes are
components of complex I and one is a component of complex II. The remaining regulated gene
is involved in mitochondrial solute transport.
We then sought to confirm the expression of these six oxidative phosphorylation genes
by quantitative real time RT-PCR (Appendix A.1). Of the six ‘hits’ from the microarray all
displayed the same downward trend with RT-PCR as by microarray, and three genes were
‘confirmed’ (Figure 3.2.A): NDUFB5 (3.19 ± 0.26 to 2.12 ± 0.20AU, p < 0.01), SDHB
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(0.26 ± 0.02 to 0.19 ± 0.02AU, p < 0.05), NDUFS1 (0.28 ± 0.03 to 0.21 ± 0.02AU, p=0.05),
SLC25A12 (0.29 ± 0.04 to 0.19 ± 0.02AU, p=0.08), NDUFB3 (0.39 ± 0.05 to 0.26 ± 0.034AU,
p=0.14) and NDUFV1 (0.36 ± 0.05 to 0.30 ± 0.04AU, p=0.32). The magnitudes of these
Table 3.3 Microarray hits - oxidative phosphorylation. By microarray analysis, 298 genes
were up- or downregulated after a HFD. Of those 298, 6 are known to be involved in oxidative
phosphorylation or mitochondrial function. NDUFB3, NADH dehydrogenase (ubiquinone) 1
beta subcomplex, 3; NDUFB5, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5;
SDHB, succinate dehydrogenase complex, subunit B; SLC25A12, solute carrier family 25
(mitochondrial carrier); NDUFV1, NADH dehydrogenase (ubiquinone) flavoprotein 1;
NDUFS1, NADH dehydrogenase (ubiquinone) Fe-S protein 1.
Gene

Fold Change

p-value

NDUFB3
NDUFB5

↓ 1.4
↓ 1.9

<0.01
<0.01

SDHB

↓ 2.4

<0.01

SLC25A12

↓ 1.8

<0.01

NDUFV1

↓ 1.9

<0.01

NDUFS1

↓ 2.4

<0.01

changes (~ 20-30%) are strikingly similar to the decreases demonstrated by microarray analysis
of reduced skeletal muscle oxidative phosphorylation gene expression found by Patti and Mootha
in diabetic subjects (83; 84). As a subsequent step in elucidating the effects of the diet
intervention on the expression of genes involved in mitochondrial function, we examined the
mRNA for genes in complex III and complex IV using qRT-PCR (Figure 3.2.A). Cytochrome C
(complex III) and Surfeit 1 (complex IV) expression levels were reduced (1.13 ± 0.07 to 0.85 ±
0.05AU, p < 0.01 and 1.10 ± 0.05 to 0.90 ± 0.05 AU, p < 0.01). Because expression levels of
genes involved in mitochondrial function decreased, we examined gene expression of those
involved in mitochondrial biogenesis. We observed a 20% and a 25% reduction in mRNA levels
in PGC1α and PGC1β, respectively (Figure 3.3.A); PGC1α (1.44 ± 0.08 to 1.13 ± 0.06 AU,
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Figure 3.2.A HFD decreases mRNA for genes involved in oxidative phosphorylation in
healthy young men. Effect of a three day isoenergetic high fat diet (50% fat vs. 35% fat) in a
cohort of healthy insulin-sensitive males (n=10) at baseline and after intervention on the
expression of genes in complex I (NDUFB3, NDUFB5, NDUFV1, NDUFS1) complex II
(SDHB), complex III (CYC1), complex IV (SURF1) and a mitochondrial carrier protein
(SLC25A12). mRNA was quantified by qRT-PCR. Data are shown as means ± SE and corrected
for the expression of 18S and RPLP0. NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 3; NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5; NDUFV1
NADH dehydrogenase (ubiquinone) flavoprotein 1; NDUFS1 NADH dehydrogenase
(ubiquinone) Fe-S protein 1); SDHB succinate dehydrogenase complex, subunit B; SLC25A12
solute carrier family 25 (mitochondrial carrier); CYC1 cytochrome c-1; SURF1 surfeit 1; 18S
18S ribosomal RNA; RPLP0 ribosomal protein, large, P0.
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baseline
HFD
complex IV

Figure 3.2.B HFD decreases mRNA for genes involved in oxidative phosphorylation in
mice. Effect of a 21 day high fat diet (45% fat vs. 10% fat) in a cohort of C57Bl/6J mice
(control, n=6; HFD, n=7) on genes in Complex I (NDUFB3 AND NDUFB5) Complex II
(SDHB), Complex III (CYC1), Complex IV (SURF1) and a mitochondrial carrier protein
(SLC25A12). Data are shown as means ± SE and corrected for the expression of Cyclophilin B.
mm mus musculus; mmNDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3;
mmNDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5; mmSLC25A12 solute
carrier family 25 (mitochondrial carrier); mmSDHB succinate dehydrogenase complex, subunit
B; mmCYC1 cytochrome c-1; mmSURF1 surfeit 1; mmCycB peptidylprolyl isomerase B
(cyclophilin B).
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p<0.01) and PGC1β (2.12 ± 0.16 to 1.59 ± 0.18 AU, p<0.05). Mitochondrial transcription factor
A (TFAM), a key activator of mitochondrial transcription and its genome replication, was not
significantly changed (2.00 ± 0.19 to 1.79 ± 0.19 AU, p=0.38), nor was nuclear respiratory factor
1, NRF1 (1.89 ± 0.13 to 1.56 ± 0.16AU, p=0.14) (Figure 3.3.A).
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Figure 3.3.A HFD decreases expression of transcriptional cofactors involved in the
regulation of oxidative phosphorylation gene expression and mitochondrial biogenesis in
healthy young men. Effect of a three day isoenergetic high fat diet (50% fat vs. 35% fat) in a
cohort of healthy insulin-sensitive males (n=10) at baseline and after intervention on the
expression of genes involved in mitochondrial biogenesis. Data are shown as means ± SE and
corrected for the expression of RPLP0. PGC1α peroxisome proliferative activated receptor,
gamma, coactivator 1, alpha; PGC1β peroxisome proliferative activated receptor, gamma,
coactivator 1, beta; TFAM transcription factor A, mitochondrial; NRF1 nuclear respiratory
factor-1; RPLP0 ribosomal protein, large, P0.
We next tested whether the changes in gene expression we found in the clinic were
present in a murine model of high fat diet-induced obesity. We fed C57Bl/6J mice either a 10%
or 45% fat diet for three weeks. We chose two murine genes from complex I, one gene each
from complexes II, III and IV and one mitochondrial carrier protein from the human
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experiments. Decline in gene expression was of greater magnitude than that seen in the human
experiments. As measured by real time qRT-PCR, each of these genes was downregulated in
high fat fed mice as compared to their controls (Figure 3.2.B): NDUFB5 (24.05 ± 7.89 to 2.10 ±
0.44AU, p < 0.01), NDUFB3 (19.02 ± 6.25 to 1.82 ± 0.29AU, p < 0.01), SDHB (10.84 ± 3.58 to
1.05 ± 0.20AU, p < 0.01) SLC25A12 (6.14 ± 1.99 to 0.45 ± 0.11AU, p < 0.01), CYC1 (10.41 ±
3.40 to 0.79 ± 0.13 AU,p<0.01), and SURF1 (175.50 ± 57.35 to 13.81 ± 3.20 AU, p<0.01).
In parallel to the human experiment, we measured both PGC1α and PGC1β mRNA in
these same mice. We found a 90% reduction in mRNA levels for both PGC1α and PGC1β
(Figure 3.3.B): PGC1α (34.63 ± 12.57 to 2.67 ± 0.31 AU, p<0.01) and PGC1β (25.75 ± 9.03 to
1.85 ± 0.30 AU, p<0.01).
It has been shown that the half-life of a mitochondrion in a mammalian cell can range
from about three days up to ten days, depending on the measurement technique
(132). Given that the expression of both PGC1α and PGC1β were decreased, we hypothesized
that skeletal muscle mitochondrial DNA copy number might be decreased by the high fat diet;
however, we found no differences between animals fed a high fat diet when compared to those
fed a low fat diet (Figure 3.3.B); mitochondrial DNA in low fat animals 1166 ± 112.50 and in
high fat animals 1127 ± 70.28 AU, p=0.78.
3.3 Discussion
Numerous studies have implicated reduced mitochondrial biogenesis and oxidative
phosphorylation in the pathogenesis of insulin resistance and Type 2 diabetes (133). Reductions
in the expression of nuclear mRNAs encoding genes involved in mitochondrial oxidative
phosphorylation have been reported in individuals with a family history of Type 2 diabetes and
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in individuals affected by Type 2 diabetes (83; 84). These studies complement earlier anatomic
and physiologic studies documenting alterations in mitochondrial number, mitochondrial enzyme
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Figure 3.3.B HFD decreases expression of transcriptional cofactors involved in the
regulation of oxidative phosphorylation gene expression and mitochondrial biogenesis in
mice. Effect of a 21 day high fat diet (45% fat vs. 10% fat) in a cohort of C57Bl/6J mice
(control, n=6; HFD, n=7) involved in mitochondrial biogenesis and mitochondrial DNA copy
number per nuclear DNA copy number. Data are shown as means ± SE and corrected for the
expression of Cyclophilin B. mmPGC1α peroxisome proliferative activated receptor, gamma,
coactivator 1, alpha; mmPGC1β peroxisome proliferative activated receptor, gamma, coactivator
1, beta; mmCOXII cytochrome c oxidase II, mitochondrial; mmUCP2 uncoupling protein 2;
mmCycB peptidylprolyl isomerase B (cyclophilin B).
activities and oxidative vs. glycolytic fiber type in skeletal muscle (123). Importantly, functional
studies of skeletal muscle energy metabolism in situ demonstrate that ATP synthesis is reduced
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in aging and the offspring of insulin resistant individuals (85; 86). The latter authors suggested
that lipid flux is not involved in the reduction in expression of OXPHOS genes because fasting
plasma NEFAs were similar in insulin-resistant and insulin-sensitive individuals, and glycerol
turnover studies did not demonstrate an increase in lipolysis. However, our data suggest that
dietary fat, or increased fat utilization in skeletal muscle, is an important factor in the
observed reduction in OXPHOS genes in insulin resistant states. Microarray analysis and
quantitative real time RT-PCR results revealed a downregulation of OXPHOS genes after eating
the HFD, as well as transcription factors and cofactors, in our human experiments. Additionally,
we have shown that the reductions in genes involved in oxidative phosphorylation and
mitochondrial biogenesis were recapitulated in an animal model of dietary-induced obesity and
insulin resistance (134) and were of a much greater magnitude in mice as compared to man.
Through the combined use of microarray technology, advanced bioinformatics and
confirmation of the microarray results with qRT-PCR, we were able to identify subtle (20-30%)
changes in OXPHOS gene expression without a priori grouping of genes based on known
function (83). The advantage of this approach is genes that do not exhibit large changes in
transcription, but that are clearly important in carbohydrate and energy metabolism (e.g.
PGC1α), may be identified. Overall, an acute HFD elicits a coordinated downregulation of
genes involved in oxidative phosphorylation within the electron transport chain. Moreover, the
expression of PGC1β is also decreased.
Our results support the hypothesis that high fat diets and/or high fat flux through the
mitochondria reduce the expression of nuclear genes encoding mitochondrial proteins and
transcription factors involved in mitochondrial biogenesis. Both PGC1α and PGC1β were
decreased by about 20% and were accompanied by a 20% reduction in OXPHOS gene
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expression. Previous studies suggest a link between the downregulation of PGC1 and
dysregulation of OXPHOS genes. Our results are consistent with this sequence of events, and
indeed three of our OXPHOS genes found by microarray analysis were also present in the
analyses of Mootha and Patti (83; 84). Therefore, our findings expand the view beyond the
relationship between PGC1 and OXPHOS genes. We move upstream to show that increased
fatty acid flux through the mitochondria decreases PGC1 expression and is associated with a
downregulation of expression of genes involved in oxidative phosphorylation. Highly
homologous to one another, PGC1α and PGC1β both alter mitochondrial metabolism but
ultimately retain different physiological functions (135). Puigserver and Spiegelman (124)
demonstrated that PGC1α is a master regulator of mitochondrial biogenesis and OXPHOS gene
expression (136). PGC1α co-activation of NRF1-mediated transcription leads to transcription
and subsequent translocation of TFAM to the mitochondrion, thus increasing mtDNA
transcription (137; 138). In these studies, both coactivators PGC1α and PGC1β were
downregulated; however, we saw no significant change in two downstream targets, NRF1 and
TFAM (Figure 3.3.A).
Although an increase in free fatty acid concentrations was not seen in this cohort, fatty
acid flux through the muscle is by necessity increased in these subjects as demonstrated by an
increase in fat oxidation to match fat intake in this experimental paradigm (90). Another
explanation for the reduction in the expression of these genes is that HFD decreases insulinstimulated gene expression. Fatty acids decrease insulin signaling both in vivo and in vitro.
Recent microarray studies demonstrate an upregulation of OXPHOS genes after a short-term
insulin infusion (139). A reduction in insulin signaling might reduce expression of these same
genes. Our studies do not identify the exact mechanism of the reduction in PGC1α, PGC1β or
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their downstream targets. Rather these studies point toward dietary fat, or increased lipolysis, as
a potential source of the previously reported reduction in mitochondrial oxidative
phosphorylation and subsequent mitochondrial dysfunction.
Importantly, mice fed a HFD for three weeks showed a similar pattern of changes in gene
expression as in the shorter (three day) human experiments. The magnitude of the changes in
gene expression was much larger in mice than in man. In light of the fact that three days of HFD
is not long enough to cause changes in mtDNA copy number as mitochondrial turnover is
relatively slow (132), we next tested the hypothesis that the changes in the transcriptional
cofactors (e.g. PGC1α and PGC1β) would decrease mitochondrial number in mice fed a HFD for
three weeks. We found large changes in PGC1α and PGC1β, but mtDNA remained unchanged
after three weeks of HFD in mice.
In some ways our inability to find changes in mitochondrial DNA copy number are
inconsistent with recent studies demonstrating a reduction in mitochondrial number in diabetes
and insulin resistance (116; 123) but similar to studies showing a decrease in OXPHOS gene
expression (83; 84). One possibility is that ‘chronic’ versus ‘acute’ effects of high fat flux
through mitochondria are different. In the prediabetic and diabetic states, increased lipid flux has
been maintained for a longer period of time. Therefore, additional studies of mitochondrial
number and function, including electron transport chain activity and electron microscopy, will be
needed to fully rule out subtle changes in mitochondrial number or function with an acute HFD.
Our studies reveal a key question: “why would increased fatty acid flux decrease the
expression of genes needed to oxidize these same fatty acids?”. Fasting is another ‘normal’
physiological condition where fatty acid flux through skeletal muscle is increased. Surprisingly,
fasting produces changes in gene expression that are strikingly similar to the pattern of fat-
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induced changes observed in our studies of high fat diets. For example, Jagoe et al found that
CASQ2 (calsequestrin 2), NDUFS1, glycogen synthase and PDK4 (pyruvate dehydrogenase
kinase isoenzyme 4), four genes found on our microarray ‘hit’ list (Appendix A.2) and confirmed
by qRT-PCR (data not shown), were similarly regulated by fasting in rodents (140). This may
explain the paradoxical decrease in systems needed to oxidize fatty acids (nuclear genes
encoding mitochondrial proteins, PGC1α) when fat flux is increased during a high fat diet. In
other words, the parallel results between fasting and high fat diets suggest that fat flux through
the skeletal muscle might be interpreted as a signal of fasting/starvation by the muscle cell itself.
Signaling systems normally reserved for responding to energy deprivation (fasting) may be coopted when dietary fat is increased. This hypothesis is also consistent with the observed changes
in the transcription of genes involved in non-oxidative metabolism (e.g. glycolysis) found on our
microarray ‘hit’ list (Appendix A.2).
In conclusion, high fat diets in both insulin-sensitive humans and in mice were associated
with a reduction in the expression of genes involved in oxidative capacity (e.g. genes of the
electron transport chain), nuclear genes encoding mitochondrial proteins (e.g. mitochondrial
carrier proteins) and those involved in mitochondrial biogenesis (e.g. PGC1α and PGC1ß).
These studies support the novel hypothesis that high fat diets or high fat flux explain the
reduction in OXPHOS genes seen in aging, the prediabetic state and in overt diabetes.
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CHAPTER 4: GLUCOSE METABOLISM VIA A LONG-TERM TRANSCRIPTIONAL
LOOP*
4.1 Introduction
Type 2 diabetes affects over 110 million people worldwide, and Type 2 diabetes
associated with obesity is reaching epidemic proportions (1, 2). Many pathophysiological
processes have been implicated in diabetes, such as pancreatic β cell dysfunction, as well as
defects in insulin signaling, carbohydrate utilization and mitochondrial metabolism (3, 4). The
earliest detectable abnormality in people at risk for Type 2 diabetes is insulin resistance in
skeletal muscle. The ability of insulin to activate signal transduction events, alter gene
expression of selected genes (5) and stimulate muscle glycogen synthesis is an integral part of
the body’s response to macronutrient intake.
The physiologic purpose of alterations in fuel selection is to channel energy to and from
the appropriate storage compartments under all circumstances that may confront the organism.
An obligate need exists to regulate glycogen within a relatively narrow window. Studies
conducted in subjects with Type 2 diabetes and in healthy subjects to determine the fate of
glucose after it is taken up by muscle cells demonstrate that muscle glycogen synthesis, along
with glycolysis, is an important pathway in skeletal muscle glucose metabolism (6). Muscle
cells adjust the fuels they oxidize in order to match substrate supply, signals from the endocrine
and neural systems and the ATP required for contraction.

* published as Metabolism: Clinical and Experimental 55: 1457-1463, 2006, with permission
from Metabolism.
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The supply of substrate to muscle tissue depends upon several factors including the
dietary macronutrient content, the storage of nutrients in liver and fat, capillary recruitment and
transport, and in the case of triglycerides, the release of free fatty acids by the enzymatic activity of
lipoprotein lipase (LPL) at the surface of the cell. The adjustment of substrate oxidation to the
local nutrient concentrations occurs through at least three mechanisms: minute-to-minute
changes in the activity of enzymes that direct carbohydrate and fat into oxidation or storage (6),
the activation of signaling pathways such as PKC (8) and NFκB (9) and through long-term
regulatory systems that involve changes in gene transcription and hence the cellular machinery
driving the first two processes. The ability of insulin to regulate glucose homeostasis, i.e. insulin
sensitivity, is closely related to these regulatory pathways, justifying further attempts to unravel
the details of these regulatory systems. Strong experimental evidence exists for each of these
pathways, particularly for the regulation of substrate utilization and insulin sensitivity through
enzyme activity (7) and signaling pathways (8). Less data is available to implicate
transcriptional pathways as key components of this autoregulatory loop. We previously
described the effects of a short-term HFD to reduce the expression of genes related to oxidative
phosphorylation within the skeletal muscle of young, healthy volunteers (10). The purpose of
this research was to expand that investigation and to identify the transcriptional responses for
other metabolic systems such as carbohydrate oxidation and storage, as well as fatty acid
oxidation.
4.2 Results
Participants presented to the Pennington Biomedical Research Center inpatient unit
(Figure 4.1) on day -4 at 07:00 PM. The characteristics of the study population are presented
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in Table 4.1. Fasting glucose, insulin and free fatty acids were unchanged as the diet was
switched from ‘standard’ fat : carbohydrate content (35% : 49%) to high fat : low

in metabolic chamber
CONTROL DIET
Day

-4

-3

-2

-1

0

HF / LC DIET
1

2

3

4

Muscle Biopsy
EH Clamp
24h RQ

0.87 ± 0.01

0.82 ± 0.01

Figure 4.1 ADAPT study design. Subjects consumed a prescribed control diet (35% fat, 49%
carbohydrate, 16% protein) followed by a euglycemic-hyperinsulinemic (EH) clamp and a
muscle biopsy. They were switched to a prescribed HF/LC diet (50% fat, 34% carbohydrate,
16% protein) and placed in metabolic chamber for a total of 4 days where fatty acid oxidation
was measured by respiratory quotient (RQ) at Day0 and Day4. They finished with a muscle
biopsy on Day4.
carbohydrate content (50% : 34%; data not shown). Intra-subject changes in skeletal muscle
gene expression before versus after three days eating the high fat/low carbohydrate diet were
identified using oligonucleotide microarrays according to low laser analysis previously
described (10).
The three-day isoenergetic high fat/low carbohydrate diet significantly changed the
expression of 298 genes according to the low laser ‘hit’ list (p < 0.01; Appendix A.2). 163 genes
were upregulated and 135 were downregulated by the high fat/low carbohydrate diet. A further
analysis of the low laser dataset revealed an additional 72 genes regulated by the intervention (p
> 0.01 < 0.05; Appendix A.4).
From these analyses, seven of those genes were known to be involved in glucose
metabolism by visual inspection or through gene ontogeny analysis (Table 4.2). Of the

45

glucose metabolism genes five were downregulated and two were upregulated. Fructose-2,6biphosphatase 3 (PFKFB3) and pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4) increased
Table 4.1 Characteristics of the study population before high fat/low carbohydr ate
d iet. T en male subjects were chosen from the larger study population based on a hig h
aerobic capacity and insulin sensitivity. BMI, body mass index; GDR, glucose disposal
rate; CHO, carbohydrate; FFA, free fatty acids.

Subject Characteristics
Age (y)
Height (cm)
Weight (kg)
BMI (kg/m ² )
WHR (au)
RQ (au)
VO 2 max (ml/kg/min)
Fasting Glucose (mg/dl)
Fasting Insulin (µU/ml)
GDR (mg/kgFFM/min)
Cumulative CHO Balance
FFA (mmol)
Body Fat (%)

Mean ± SD

Range

23.0 ± 3.1
179.7 ± 6.3
78.9 ± 13.2
24.3 ± 3.0
0.88 ± 0.1
0.87 ± 0.02
49.4 ± 4.0
78.4 ± 4.7
4.6 ± 1.4
14.7 ± 4.1
139.9 ± 163.9
0.4 ± 0.1
16.2 ± 3.2

18.0 – 28.0
170.6 – 189.5
61.7 – 104.8
21.0 – 30.7
0.8 – 1.0
0.85 – 0.90
45.5 – 56.1
70.0 – 86.0
2.6 – 7.6
9.9 – 24.5
-208.8 – 297.5
0.07 – 0.50
11.5 – 20.4

at the RNA expression level, while glycogen synthase 1, muscle (GYS1), galactose-1-phosphate
uridyltransferase (GALT), pyruvate dehydrogenase, beta subunit (PDHB), mitogen-activated
protein kinase kinase 3 (MAP2K3) and UDP-glucose pyrophosphorylase 2 (UGP2) decreased in
expression.
All of the genes are involved in the oxidation and storage of glucose, or glucose
transporter expression (18). All qRT-PCR results are based on the seven genes from the initial
low laser analysis (p < 0.01). Within this cohort of insulin-sensitive males, although circulating
free fatty acid (FFA) concentrations did not increase (Figure 4.2.A), we were able to demonstrate
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an increase in fatty acid oxidation on the HF / LCD as measured by a significant decrease in their
respiratory quotient (RQ) during their four-day stay in the metabolic chamber (Figure 4.2.B):
(0.87 ± 0.01 to 0.82 ± 0.01AU, p < 0.01). Due to phenotypic changes in the subjects as
Table 4.2 Microarray hits in glucose metabolism pathways. By microarray analysis, a total of
370 genes were up- or downregulated after a HF/LCD. Of those 370, 7 are known to be involved
in glucose metabolism. PFKFB3, fructose-2,6-biphosphatase 3; PDK4, pyruvate dehydrogenase
kinase, isoenzyme 4; GYS1, glycogen synthase 1 (muscle); GALT, galactose-1-phosphate
uridyltransferase; PDHB, pyruvate dehydrogenase, beta subunit; MAP2K3, mitogen-activated
protein kinase kinase 3; UGP2, UDP-glucose pyrophosphorylase 2.
Gene

Fold Change

p-value

PFKFB3
PDK4
GYS1
GALT

↑ 3.3
↑ 1.7
↓ 1.7
↓ 1.6

<
<
<
<

PDHB

↓ 1.7

< 0.01

MAP2K3

↓ 2.0

< 0.01

UGP2

↓ 2.0

< 0.01

0.01
0.01
0.01
0.01

evidenced by a decrease in RQ, as well as displaying a positive carbohydrate balance subsequent
to intervention, we then sought to confirm the expression of these glucose metabolism genes by
real time qRT-PCR (Appendix A.3). Of the ‘hits’ from the low laser microarray list (p < 0.01),
three genes were confirmed (Figure 4.3.A): PDK4 (0.09 ± 0.01 to 0.16 ± 0.03AU, p < 0.01),
PFKFB3 (1.61 ± 0.26 to 3.28 ± 0.52AU, p < 0.01) and GYS1 (2.17 ± 0.17 to 1.71 ± 0.16AU, p <
0.01).
We next tested whether the changes in gene expression that we found in the clinic were
present in a murine model of high fat/low carbohydrate diet-induced obesity. We fed
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C57Bl/6J mice either a 10% : 70% or 45% : 35% high fat/low carbohydrate diet for three weeks.
We chose two murine genes involved in glucose oxidation and two genes involved in glucose
A

B
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Figure 4.2 HF/LCD shifts substrate utilization toward fatty acid oxidation. (A) Effect of a
three-day isoenergetic high fat/low carbohydrate diet (50% : 34% fat) in a cohort of healthy
insulin-sensitive males (n=10) on circulating free fatty acid (FFA) concentrations during their stay
in the metabolic chamber. (B) Effect of a three-day isoenergetic high fat/low carbohydrate diet
(50% : 34% fat) in a cohort of healthy insulin-sensitive males (n=10) on fatty acid oxidation as
measured by respiratory quotient (RQ) during their stay in the metabolic chamber.
storage from the human experiments. The changes in gene expression were in the same direction,
but of a greater magnitude than those seen in the human experiments. As measured by real time
qRT-PCR the results in rodents matched those in man (Figure 4.3.B): PDK4 (0.31 ± 0.03 to 1.05
± 0.07AU, p < 0.01), PFKFB3 (0.65 ± 0.04 to 1.08 ± 0.17AU, p < 0.01), GYS1 (3.60 ± 0.66 to
0.66 ± 0.06AU, p < 0.01) and GALT (4.37 ± 0.89 to 0.81 ± 0.07AU, p < 0.01).
4.3 Discussion
During insulin stimulation the skeletal muscle is the major site for glucose disposal (19),
thus defects in insulin-mediated glucose uptake and in its metabolic fate in this tissue are thought
to be responsive to the macronutrient composition of the diet. Since Randle’s proposal in 1963
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(7) of a glucose-fatty acid cycle that embodies direct competition between substrates for
mitochondrial oxidation, a plethora of mechanisms have been put forward to explain how fuel
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Figure 4.3.A HF/LCD regulates mRNA for genes involved in glucose metabolism in healthy
young men. Effect of a three-day isoenergetic high fat/low carbohydrate diet (50% : 34% fat) in
a cohort of healthy insulin-sensitive males (n=10) at baseline and after HF/LCD intervention on
the expression of genes involved in glucose oxidation (PFKFB3 and PDK4) and glucose storage
(GYS1). mRNA was quantified by qRT-PCR. Data are shown as means ± SE and corrected for
the expression of RPLP0. PFKFB3 fructose-2,6-biphosphatase 3; PDK4 pyruvate dehydrogenase
kinase, isoenzyme 4; GYS1 glycogen synthase 1 (muscle); RPLP0 ribosomal protein, large, P0.
Substrates could interfere with glucose disposal in skeletal muscle (20-22). In vivo, release
and/or intermediate products of lipid fuels (fatty acids and ketone bodies, respectively) released
into the circulation (e.g. in starvation or diabetes) may inhibit the catabolism of glucose in
muscle, as well as its storage (8, 23).
Although an increase in free fatty acid concentrations was not seen in this cohort (Figure
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4.2.A), fatty acid flux through the muscle is by necessity increased in these subjects as
demonstrated by a decrease in 24h respiratory quotient (RQ; Figure 4.2.B) to match the fat
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Figure 4.3.B HF/LCD regulates mRNA for genes involved in glucose metabolism in mice.
Effect of a 21–day ad libitum feeding of a high fat/low carbohydrate diet (45% : 35%) in a
cohort of C57Bl/6J mice (control, n=6; HF/LCD, n=7) on genes involved in glucose oxidation
(PFKFB3 and PDK4) and glucose storage (GYS1 and GALT). Data are shown as means ± SE
and corrected for the expression of Cyclophilin B. PFKFB3 fructose-2,6-biphosphatase 3; PDK4
pyruvate dehydrogenase kinase, isoenzyme 4; GYS1 glycogen synthase 1 (muscle); GALT
galactose-1-phosphate uridyltransferase.
intake in this experimental paradigm (11). Therefore, substrate utilization is shifting more
toward oxidation of fatty acids by reducing the oxidation of glucose; the uptake and utilization of
glucose should consequently be reduced. A negative carbohydrate balance occurs immediately
after consumption (one to two days) of a HF/LCD indicating a continued glucose oxidation and
glycogen depletion as fat oxidation takes days to catch up to fat intake (31, 36). A positive
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carbohydrate (CHO) balance was observed at the end of the three-day HF/LCD in this cohort of
healthy young males, thus indicating a decrease in glucose oxidation (Table 4.1). We also
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Figure 4.4 Transcriptional regulation of glucose flux. Upon entry into the muscle cell, glucose
can either be oxidized via glycolysis and enter the TCA cycle or it can be stored as glycogen and
galactose via non-oxidative glucose metabolism. The 9 genes that were altered by a three-day
HF/LCD in human skeletal muscle according to low laser microarray analysis are marked blue if
downregulated and red if upregulated. PFKFB3 fructose-2,6-biphosphatase 3; PDK4 pyruvate
dehydrogenase kinase, isoenzyme 4; GYS1 glycogen synthase 1 (muscle); GALT galactose-1phosphate uridyltransferase; PDHB pyruvate dehydrogenase, beta subunit; UGP2 UDP-glucose
pyrophosphorylase 3; MAP2K3 mitogen-activated protein kinase kinase 3; FBP1 fructose-1,6biphosphatase; HK hexokinase; PFK phosphofructokinase.

observed a decrease in the messenger RNA levels of a number of genes involved in the
oxidative, as well as the non-oxidative, glucose metabolism. Even more striking is the matching
murine data showing a greater magnitude of change with a longer exposure to a high fat/low
carbohydrate diet (three days versus three weeks). The extent of the effects of high fat/low
carbohydrate dietary intake on muscle glucose metabolism reflects the length of each model’s
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exposure to the diet. For example, the human cohort responded with about a 30% change in
gene expression after three days of high fat/low carbohydrate diet; whereas, the murine model had
about a 70% change in gene expression with three weeks of exposure. These results indicate
that the effects of the HF/LCD are not transient. Even more compelling is the concurrent
change in phenotype, such as decreased RQ (Figure 4.2.B), positive CHO balance (Table 4.1)
and the changes in the genes controlling glucose metabolism in response to the perturbation of
this diet (Table 4.2).
A variety of model systems have largely confirmed the validity of Randle’s experiments
depicting the mechanism of substrate competition through changes in enzymatic activity as a
result of product feedback inhibition, at least in terms of the acute effects of fatty acids on muscle
glucose metabolism and storage (24, 25). Our results supplement those of Randle by
demonstrating a downregulation of genes involved in glucose oxidation and storage when fat
intake is increased and carbohydrate intake is decreased. Our findings relate to changes in
mRNA expression only, and we acknowledge that many of the enzymes involved in glycolysis
and glycogen synthesis are regulated allosterically, and through covalent modification.
Transcriptional regulation (Figure 4.4) may enhance the Randle cycle or changes in the
activation of signaling molecules / pathways such as PKC or ceramides (8, 21).
Through the use of bioinformatics and microarrays, we expand the view of the glucosefatty acid cycle beyond enzymatic activity to the level of gene transcription. In
our analyses of the low laser microarray data set (Appendix A.2 and Appendix A.4), we found
over 300 genes regulated by a three-day high fat/low carbohydrate diet in our human subjects.
Four of our glucose metabolism genes (PFKFB3, PDK4, PDHB and GALT) were found in the
analyses, and two of the four genes were confirmed by qRT-PCR. This is consistent with the
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noise inherent to current microarray technologies (26, 27). After reporting changes in
expression of the genes in the glucose metabolism gene cluster, we are left with the question of
how the macronutrient composition of the diet affects other genes. The HF/LCD significantly
regulated the expression of many OXPHOS genes, a few genes involved in fatty acid
metabolism and various other genes known and unknown (Appendix A.2 and Appendix A.4).
Recent studies suggest that both acute and chronic increases in fatty acids downregulate
oxidative phosphorylation in skeletal muscle (10, 23). Cluster analysis suggests that the changes
in OXPHOS genes and the carbohydrate metabolism genes described herein are involved in a
long-term transcriptional loop; however, the identity of the overall transcriptional control system
remains unknown. It has been suggested that PGC1α plays a pivotal role as a link between a
high fat diet and oxidative phosphorylation (87). Furthermore, the implication that both
OXPHOS and carbohydrate metabolism genes are regulated at the transcriptional level is
important for two reasons: (1) the unidentified transcriptional control system may be a ‘master
regulator’ of energy homeostasis for both glucose and mitochondria and (2) strategies to identify
the key regulators of this system should include both subsets of these genes.
Consonant with recent evidence by Pehleman et al (28) demonstrating the enzymatic
regulation of glucose disposal in human skeletal muscle after a high fat/low carbohydrate diet,
our results expand this view to a transcriptional co-regulation of glucose metabolism in this same
tissue, as well as murine skeletal muscle after a high fat/low carbohydrate diet. Pehleman et al
found a dramatic decrease in the activity of pyruvate dehydrogenase (PDH) with a concomitant
increase in the enzymatic activity of PDH kinase (PDK) in response to a 56h eucaloric high
fat/low carbohydrate diet (73% : 5%) within a healthy human cohort of insulin-sensitive males.
While our results are not as dramatic, probably due to difference in dietary fat/carbohydrate
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content (50% : 34% vs. 73% : 5%), we do show the same effects on PDK at the level of
transcription. Together, our results identify both enzymatic activity and gene expression as
targets of the transcriptional regulation.
Several studies over the past decade have shown pyruvate dehydrogenase kinase 4
(PDK4) message, protein and activity decrease as a result of increased free fatty acids, starvation
and diabetes (30-32). More recently, PDK4 has become the target of diabetic drug investigations
(33, 34). PDK4 promotes gluconeogenesis and suppresses glucose oxidation and maintains
glucose levels in starvation. Although prior studies bolster the credibility of PDK4 as a diabetic
drug target, our result argues against this view. We demonstrate that while glucose oxidation is
suppressed, the transcription of genes before and after PDK4 is downregulated by HFD. Thus,
the inactivation of PDK4 might not be effective in the setting of HFD / ‘lipotoxicity’.
The original studies which formed the basis of the glucose-fatty acid cycle (7, 22, 35,
36) elucidated (1) fatty acid-induced desensitization of insulin-mediated glucose transport and
(2) inhibitory effects of increased fatty acid oxidation on glucose metabolism. According to the
Randle hypothesis (7, 24), an increase in lipid oxidation in muscle will decrease glucose
oxidation by suppression of the mitochondrial pyruvate dehydrogenase complex, with a
consequential reduction of glycolytic flux resulting in an increase in glucose-6-phosphate,
inhibition of hexokinase activity and ultimately leading to decreased glucose uptake. Nonoxidative metabolism (storage) of glucose is, therefore, also predicted to be decreased. This
mechanism has been reexamined and evolved over the past few decades (37), but the cellular
effect is consistently observed. Differences in glucose-6-phosphate levels and mechanisms
aside, a consistently observed effect of increased fat intake is the reduction of non-oxidative
glucose metabolism (38). This data provides a basis for a transcriptional switch to regulate
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substrate utilization within the skeletal muscle in response to changes in dietary macronutrient
content. Overall, the novel contribution of this paper is its identification of multiple regulated
genes within the same pathway by high fat/low carbohydrate diet.
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CHAPTER 5: A ROLE FOR ADIPOSE TISSUE INFLAMMATION IN METABOLIC
INFLEXIBILITY
5.1 Introduction
A key feature of the Type 2 diabetes (T2D) is metabolic inflexibility, which is
characterized by impaired fasting fat oxidation and decreased insulin-stimulated glucose
oxidation. Metabolic inflexibility is defined as an inability to transition between the utilization
of lipids (fasting) and carbohydrates (after a meal). In obese individuals key features of
metabolic inflexibility are (1) failure of skeletal muscle to appropriately move between use of
lipid in the fasting state and use of carbohydrate in the insulin-stimulated state and (2) impaired
transitioning from fatty acid efflux to storage (71). Obesity, hyperglycemia, impaired insulin
stimulation of skeletal muscle glucose uptake (141), impaired mitochondrial biogenesis and
decreased capacity for oxidation of dietary fat are all involved in the state of metabolic
inflexibility (72). Furthermore, these physiologic characteristics are enriched in healthy young
men with a family history of Type 2 diabetes (Ukropcova, B; in review).
White adipose tissue (WAT) is a major site of energy storage and is important for energy
homeostasis: it stores energy in the form of triglycerides during nutritional abundance and
releases energy as FFAs during nutritional deprivation (142; 143). While WAT provides a
survival advantage in times of starvation, excess WAT and adipocyte hypertrophy are now
linked to obesity-related health problems in the current nutritionally rich environments of
developed countries. Furthermore, while adipocytes are traditionally known as a fat storage
depot, they have recently been recognized as an endocrine organ that secretes hormones and
cytokines as a metabolic response. Increased basal/fasted lipolysis in white adipose tissue leads
to increased fasting FFA levels, which have been linked to insulin resistance (57). Increased
chemotaxis and macrophage content in WAT are characteristics of the obese state. These
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disturbances make the dysfunctional adipocyte a potential upstream ‘causal’ factor in metabolic
inflexibility.
Taken together, this suggests that the quantity (body fatness) and the characteristics of the
adipose tissue (adipocyte hypertrophy, disordered lipid metabolism, inflammation) might
contribute to metabolic inflexibility. To explore this hypothesis, we studied 56 healthy young
men under carefully controlled conditions, examining how adipose tissue mass and quality
influence metabolic flexibility during a euglycemic-hyperinsulinemic clamp.
5.2 Results
Subject characteristics are listed in Table 5.1. All subjects were healthy young males
ranging widely in BMI and percent body fat (20.1 – 34.7 kg/m2 and 8.4 – 32.3 %, respectively).
The respiratory quotient was measured before and during the euglycemic-hyperinsulinemic
clamp (EHC) to determine metabolic flexibility (∆RQ). ∆RQ varied greatly ranging from
inflexible to flexible (0.03 – 0.25). Lower ∆RQ was associated with higher percent body fat
(ANOVA, p < 0.05; Figure 5.1.A) and larger fat cell size (ANOVA, p = 0.05; Figure 5.1.B).
Lower serum adiponectin levels were associated with lower ∆RQ (ANOVA, p < 0.05; Figure
5.1.C).
Obesity and hypertrophic adipocytes are associated with increased fasting FFAs and
insulin-resistant adipocytes. To determine the contribution of disturbances in lipid metabolism,
we explored the relationship between fasting and insulin-suppressed FFAs and metabolic
flexibility. ∆RQ was not related to fasting FFAs (ANOVA, p > 0.05; Figure 5.1.D); however,
higher concentrations of insulin-suppressed FFAs after a 2h insulin infusion were associated with
a lower ∆RQ (ANOVA, p < 0.05; Figure 5.1.E). Fat cell size (FCS) was positively correlated
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with fasting and insulin-suppressed free fatty acids (FFAs) during euglycemic-hyperinsulinemic
clamp (EHC) (data not shown).
Table 5.1 Characteristics of the study population. All male subjects were chosen fro m the
larger mixed gender study population. *during insulin infusion (80mIU/m2 BSA/min).
BMI, body mass index; GDR, glucose disposal rate; WHR, waist to hip ratio; FFA, f ree
fatty acids.
Subject Characteristics
Age (y)
Height (cm)
Weight (kg)
BMI (kg/m ² )
WHR (au)
Body Fat (%)
Visceral a dipose tissue mass (kg)
Fasting RQ (au )
Ste ady State* RQ (au)
∆RQ (au)
VO 2 max (ml/kg/min)
Fasting Glucose (mg/dl)
Steady State* Glucose (mg/dl)
Fasting Insulin (µU/ml)
Steady State* Insulin (µU/ml)
C-peptide (ng/ml)
GDR (mg/kgFFM/min)
Fasting FFA (mmol)
Steady State* FFA (mmol)
Fat cell size (µl)

Mean ± SD

Range

22.6 ± 3.2
176.9 ± 5.8
82.5 ± 13.2
26.4 ± 4.1
0.87 ± 0.07
20.3 ± 6.5
2.1 ± 1.3
0.84 ± 0.04
0.93 ± 0.04
0.07 ± 0.15
41.2 ± 7.2
80.5 ± 5.4
89.02 ± 4.5
8.2 ± 4.6
160.1 ± 35.7
1.93 ± 0.70
11.1 ± 4.1
0.6 ± 0.2
0.05 ± 0.02
0.6 ± 0.2

18.0 – 29.0
163.0 – 189.5
59.2 – 118.3
20.1 – 34.7
0.7 – 1.0
8.4 – 32.3
0.5 – 5.7
0.74 – 0.95
0.85 – 1.03
-0.96 – 0.25
23.5 – 59.2
66.0 – 90.0
78.0 – 102.0
2.6 – 22.4
103.9 – 251.3
0.9 – 3.5
4.0 – 24.5
0.07 – 0.84
0.02 – 0.16
0.22 – 0.95

Given the relationship between adipocyte hypertrophy, disordered lipid metabolism and
metabolic inflexibility, we examined mRNA expression of candidate genes involved in lipid
metabolism (lipid synthesis, uptake, oxidation and storage, as well as lipolysis) and inflammation
(chemokines and macrophage markers) and related these to insulin-suppressed free fatty acids
(FFAs) and metabolic flexibility (change in respiratory quotient; ∆RQ) (Table 5.2). Insulinsuppressed FFAs were significantly correlated with the expression of genes involved in
58

Figure 5.1 Body fatness, FFAs, and adiponectin are related to metabolic inflexibility (∆RQ)
in healthy young men. Change in respiratory quotient (∆RQ; metabolic flexibility) was
measured before and during a euglycemic-hyperinsulinemic clamp (EHC) in the population of 56
healthy young men. ∆RQ was subdivided into quartiles and correlated with clinical
measurements. Lower ∆RQ was associated with higher percent body fat (A), and larger fat cell
size (B). Lower serum adiponectin levels were associated with lower ∆RQ (C). Lower ∆RQ
was not related to fasting FFAs as measured by enzyme assay (D); however, lower ∆RQ was
associated with higher levels of insulin-suppressed FFAs during steady state of the EHC (E) as
measured by high performance liquid chromatography (HPLC). ANOVA was used to test for
differences in biopsy and blood parameters across quartiles of metabolic flexibility (∆RQ), with
post-hoc testing by mean equality contrast between different groups using the Tukey-Kramer
HSD; alpha = 0.05. Type I error rate was set a priori at p < 0.05. Data are shown as means +
SE. All Levels not connected by same letter are significantly different.
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chemotaxis (MCP-1 and MIP-1α) and markers of macrophage content (CD68 and MAC2) (Table 5.2).
Metabolic flexibility (∆RQ) was negatively correlated with MCP-1, MIP-1α,
CD68 and MAC-2 (Table 5.2). The expressions of these four genes were highly
Table 5.2 Relationships between adipose tissue gene expression, glucose disposal,
fasting free fatty acids and insulin-suppressed free fatty acids (R2). All data are
presented as R 2 . *p < 0.01, **p ≤ 0.05. § during insulin infusion
(80mIU/m 2 BSA/min). GDR, glucose disposal rate; FCS, fat cells size; FFA, free
fatty acids; ∆RQ, delta respiratory quotient; LPL, lipoprotein lipase; FAS, fatty
acid synthase; PCK1, phosphoenolpyruvate carboxykinase 1; SCD1, stearoyl-CoA
desaturase; MCAD, acyl-Coenzyme A dehydrogenase C-4 to C-12 straight chain; CAP,
cbl-associated protein; ATGL, adipose triglyceride lipase; HSL, hormone-sensitive
lipase; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory
protein 1, alpha subunit.
Functional
Category
Lipid Uptake

Lipid Synthesis
Lipid Storage
Lipid Oxidation

Lipolysis

Inflammation

Gene
Expression
(mRNA)
CD36
LPL
FAS
PCK1
PPAR 1
PPAR 2
SCD1
MCAD
PPARa
perilipin
CAP
ATGL
HSL
CD68
MAC-2
MCP-1
MIP-1a

Fasting Steady
∆RQ
State
FFAs FFAs§
0.07
-0.02
-0.01
-0.06
0.00
0.00
0.00
0.00
0.08
-0.03
0.00
-0.06
-0.13**
0.07
-0.06
-0.05
0.00
0.05
0.08
-0.07
-0.06
-0.08
0.00
0.00
0.19* -0.05
-0.16* -0.01
-0.05
0.00
-0.02
0.06
0.05
0.04
0.00
0.01
0.06
-0.05
-0.01
0.00
-0.06
0.06
0.17*
-0.08** -0.06
-0.14** -0.01
0.01
0.14** -0.10** -0.07
-0.10** -0.01
0.00
0.07
-0.01
0.00
-0.02
-0.01
0.00
0.10** -0.02
0.00
-0.03
-0.03
0.01
0.11** -0.02
-0.02
-0.01
-0.01
0.00
0.19* -0.08** -0.05
-0.08** -0.03
0.00
0.10** 0.04
0.38* -0.10**
-0.02
0.07
0.20* -0.10**
-0.02
0.08
0.07
0.01
0.23* -0.11**
0.00
0.04
0.04
0.01
-0.10** 0.20*
0.18*
0.10** 0.20* -0.16*
GDR

% Fat

FCS

intercorrelated with R2 ranging from 0.35 – 0.78 (data not shown). FCS was positively
correlated with the chemokine MIP-1α (data not shown) and the macrophage marker
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CD68 (data not shown). There was no relationship between fasting FFAs and the
chemokines MCP-1 and MIP-1α; however, insulin-suppressed FFAs were positively
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Figure 5.2 Relationships between metabolic inflexibility (∆RQ) and expressions of
chemokines and macrophage markers. The change in respiratory quotient (∆RQ) was
divided into quartiles and correlated with gene expressions of chemokines and
macrophage markers in adipose tissue of 56 young healthy men. Both MCP-1 expression
(A) and MIP-1α expression (B) were negatively correlated with ∆RQ. Both CD68
expression (C) and MAC-2 expression (D) were also negatively correlated with ∆RQ.
mRNA expression data were normalized to 18S. Delta RQ (∆RQ) was subdivided into
quartiles. Data are shown as means + SE. All pairs were compared using Tukey-Kramer
HSD, alpha = 0.05. Levels not connected by same letter are significantly different.
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Figure 5.3 Oxidative and non-oxidative carbohydrate (CHO) disposal are related to
metabolic inflexibility (∆RQ) in healthy young men. Higher fasting carbohydrate
(CHO) oxidation (A) was associated with lower ∆RQ. Lower levels of insulinsuppressed CHO oxidation (B) and storage (C) were associated with lower ∆RQ. Delta
RQ (∆RQ) was subdivided into quartiles. ANOVA was used to test for differences in
biopsy and blood parameters across quartiles of metabolic flexibility (∆RQ), with posthoc testing by mean equality contrast between different groups using the Tukey-Kramer
HSD; alpha = 0.05. Type I error rate was set a priori at p < 0.05. Data are shown as
means + SE. All Levels not connected by same letter are significantly different.
were positively correlated with CD68 and MAC-2 (Table 5.2).
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correlated with MCP-1 and MIP-1α (Table 5.2). There was no relationship between the
macrophage markers CD68 and MAC-2 and fasting FFAs. Insulin-suppressed FFAs
We divided metabolic flexibility (∆RQ) into quartiles (quartile 1 = ∆RQ < 0.06;
quartile 2 = 0.06 < ∆RQ < 0.08; quartile 3 = 0.08 < ∆RQ < 0.11; quartile 4 = ∆RQ >
0.11) and compared quartiles to adipose tissue inflammatory gene expression. The
chemokines MCP-1 and MIP-1α were higher in inflexible subjects (lower ∆RQ)
(ANOVA, p < 0.05; Figure 5.2.A and ANOVA, p < 0.05; Figure 5.2.B, respectively), as
were the macrophage markers CD68 and MAC-2 (ANOVA, p < 0.05; Figure 5.2.C and
ANOVA, p < 0.05; Figure 5.2.D).
Metabolic inflexibility is described as both higher fasting glucose oxidation (high
RQ) and lower insulin-stimulated glucose oxidation (low RQ). To explore the
contribution of these two possibilities, we calculated fasting glucose oxidation, as well as
oxidative and non-oxidative glucose disposal. Lower ∆RQ (metabolic inflexibility) was
associated with higher fasting carbohydrate (CHO) oxidation (ANOVA, p < 0.05; Figure
5.3.A), while lower insulin-suppressed CHO oxidation was associated with lower ∆RQ
(ANOVA, p < 0.05; Figure 5.3.B). Lower non-oxidative CHO disposal (CHO storage)
was associated with lower ∆RQ (ANOVA, p < 0.05; Figure 5.3.C). Upon insulin
stimulation, CHO storage was significantly greater than CHO oxidation for both flexible
(higher ∆RQ) and inflexible subjects (lower ∆RQ) (0.57 ± 0.06 vs. 0.22 ± 0.02 g/min and
0.43 ± 0.05 vs. 0.20 ± 0.01 g/min, respectively; data not shown).
5.3 Discussion
Increased body fatness, coupled with adipocyte hypertrophy, is a determinant of
metabolic inflexibility. While metabolic flexibility varied greatly (0.03 – 0.25) across the
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cohort of 56 healthy young males, those with a higher percentage of body fat and larger
fat cells were more inflexible (lower ∆RQ). Obesity and hypertrophic adipocytes are
associated with increased free fatty acids (FFAs) and insulin-resistant adipocytes. In the
present study, lower serum adiponectin levels were associated with metabolic
inflexibility. Fat cell size (FCS) was positively correlated with fasting and insulinsuppressed FFAs, which are essentially free fatty acid levels upon insulin stimulation
during steady state of a euglycemic-hyperinsulinemic clamp (EHC); however, metabolic
inflexibility was not related to fasting FFAs. In fact, the novel finding we describe is a
relationship between metabolic inflexibility and insulin-suppressed FFAs.
Adipocyte hypertrophy and metabolic inflexibility are also related to disordered lipid
metabolism. Our results revealed that higher insulin-suppressed FFAs were associated
with higher gene expressions of certain macrophage markers (CD68 and MAC-2) and
chemokines (MCP-1 and MIP-1α); however, fasting FFAs were not related to any of the
inflammatory gene expressions. Fat cell size was positively correlated with the
macrophage CD68 and the chemokine MIP-1α. The expressions of these mRNAs
suggest a presence of macrophages and chemokines, as in the inflammatory state.
Furthermore, their increased expression as insulin-suppressed free fatty levels increase
supports a relationship between macrophage infiltration and chemotaxis and a reduced
ability of the adipose tissue to respond to insulin’s signal of lipolysis suppression. Even
more striking was that mRNA expression of both the macrophage markers and the
chemokines coordinately increased, suggesting an interdependent, and perhaps causal,
relationship between the two groups. Our results also revealed that metabolically
inflexible subjects had higher gene expressions of both macrophage markers (CD68 and
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Figure 5.4 Metabolic flexibility was affected by body fatness, adipocyte
hypertrophy, chemokines and macrophage content and adiponectin. Energy excess
leads to increased body fatness (%) and hypertrophic adipocytes. Hypertrophic
adipocytes secrete chemokines and lead to macrophage infiltration. The macrophageinfiltrated hypertrophic adipocytes decrease insulin stimulated suppression of lipolysis, as
well as decrease adiponectin secretion. Elevated levels of FFAs during steady state
(insulin infusion), coupled with decreased serum adiponectin levels, lead to an inhibition
of insulin-stimulated glucose uptake and oxidation in skeletal muscle and a decreased
capacity for fat oxidation.
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MAC-2), as well as both chemokines (MCP-1 and MIP-1α). These relationships
implicate adipocyte hypertrophy, increased chemokines and macrophage infiltration as
causes of an impaired insulin suppression of FFAs and metabolic inflexibility. The
expression of genes involved in chemotaxis and macrophage content are higher in obesity
and related metabolic disorders (144-149). Metabolic inflexibility is classically described
as both higher fasting glucose oxidation (high RQ) and lower insulin-stimulated glucose
oxidation (low RQ). Metabolically inflexible subjects had higher fasting carbohydrate
(CHO) oxidation and both lower insulin-stimulated CHO oxidation and storage.
Metabolic flexibility is affected by body fatness, adipocyte hypertrophy,
chemokines and macrophage content. This data is consistent with a model where energy
excess increases body fat and adipocytes become hypertrophic. Hypertrophic adipocytes
secrete chemokines, such as MCP-1, that recruit macrophages, leading to macrophage
infiltration of adipose tissue. The macrophage-infiltrated hypertrophic adipocytes secrete
cytokines that decrease adipocyte insulin sensitivity leading to impaired suppression of
FFAs. Taken together, these disturbances in adipocyte functioning lead to decreased
insulin-stimulated glucose uptake and oxidation, as well as a decreased capacity for fat
oxidation in skeletal muscle (Figure 5.4). This model and experimental data are
consistent with a growing body of literature.
For example, FFAs suppress insulin-stimulated glucose disposal. Boden et al
showed that FFA infusion during a clamp leads to proportional inhibitions of insulinstimulated glucose uptake and of intracellular glucose utilization (150). Heilbronn et al
has shown that administration of recombinant adiponectin in rodents increases glucose
uptake and fat oxidation in muscle and improves whole body insulin resistance (151).
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Additionally, recent studies by Civitarese et al demonstrated that low adiponectin levels
are associated with low mitochondrial DNA (mtDNA) copy number, as well as decreased
mitochondrial functions (152).
To date, the accepted idea has emerged that chronic activation of the
inflammatory pathway can be a mechanism for certain obesity-related metabolic
disorders, such as Type 2 diabetes (28). Consequently, while there is no question that the
inflammatory pathway becomes activated in adipose tissue in various obese states, and
that this negatively impacts insulin action in adipocytes, the total contribution of adipose
tissue as a source of these cytokines and/or chemokines is still unclear. In this respect,
recent attention has focused on the potential role of macrophages in this process (153).
Weisberg et al. and Xu et al. have shown that in obesity, adipose tissue contains an
increased number of resident macrophages and that, in some circumstances, macrophages
can constitute up to almost half of the cell population within an adipose tissue depot (22;
23). Macrophages have been shown to be a potential source of secreted proinflammatory
factors, and these data have led to the concept that macrophages can directly influence
adipocyte biology and ultimately lead to a state of insulin resistance.
Immunohistochemical analysis from Weisberg et al. of human subcutaneous adipose
tissue revealed that the percentage of cells expressing the macrophage antigen CD68 was
significantly and positively correlated with both adipocyte size and body mass (22).
Enlarged adipocytes are associated with metabolic inflexibility and are an
independent predictor of Type 2 diabetes. To understand the molecular link between
these diseases and adipocyte hypertrophy, Jernas, et al. developed a technique to separate
human adipocytes from an adipose tissue sample into populations of small cells and large
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cells. They identified genes with markedly higher expression in large, compared with
small, human adipocytes, and they concluded that these genes may link hypertrophic
obesity to Type 2 diabetes (154). This transcriptional link between adipocyte
hypertrophy and insulin resistance is complementary to our data showing a physiological
link between adipocyte hypertrophy and impaired insulin suppression of lipolysis, which
leads to metabolic inflexibility. The risk of metabolic complication is increased not only
by the amount and location of adipose tissue, but also by the size of the fat cells. Human
fat cells can change 20-fold in diameter and several thousand-fold in volume. Lipid
mobilization and glucose metabolism are increased in enlarged adipocytes (155). In
contrast, the stimulating effect of insulin on the rate of glucose metabolism is inversely
related to the size of the fat cell (156; 157). Cytokine release within adipose tissue also
appears to be correlated with adipocyte size (158-161), and hypertrophic adipocytes may
contribute to lipotoxicity (162). Thus, adipocyte hypertrophy leads to macrophage
infiltration and chemotaxis, ultimately resulting in an impaired insulin suppression of free
fatty acids.
FFA levels are pivotal in complex disease states such as T2D, as well as those that
precede it, such as metabolic inflexibility. Recent studies by Bajaj et al. (163)
demonstrate an improvement in peripheral insulin action in response to a 7-day reduction
of plasma FFAs in Type 2 diabetics. Experiments by Hickner et al. (164) in which they
used a microdialysis technique to determine suppression of whole body and regional
lipolysis by insulin in sedentary pre-menopausal women revealed a resistance to the
suppression of lipolysis by insulin in obesity. Correlated with intraabdominal fat mass,
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this impaired insulin suppression of lipolysis leads to an increase in FFA availability
primarily in the liver and muscle, as well as other organs.
Past studies have shown that fat infusions (163) inhibit carbohydrate metabolism.
An impaired insulin suppression of lipolysis leads to excess circulating free fatty acids.
Accumulation of excess fatty acids in the form of triacylglycerol (TAG) in skeletal
muscle and in liver is associated with metabolic inflexibility (70; 165; 166). This
increase in fat flux leads to ‘metabolic inflexibility’ whereby the skeletal muscle is
unable to switch substrates from fat to carbohydrate. The link between adipose tissue and
metabolic flexibility emphasizes the important role of adipose tissue in buffering the
daily influx of dietary fat entering the circulation and preventing excessive exposure of
other tissues to this fat influx.
Body fatness, chemotaxis, macrophage infiltration and impaired insulin
suppression of FFAs combine to contribute to a diminished capacity of substrate
switching from that of fat oxidation to carbohydrate oxidation as measured by the change
in respiratory quotient when infused with insulin. Currently, the literature points the
finger at inflammation, particularly macrophage infiltration (167-172), as the culprit in
obesity that eventually leads to metabolic disorders such as Type 2 diabetes. However, to
date no one has determined the cause. Our study has implicated a middle man between
metabolic disorders related to obesity, such as metabolic inflexibility and the state of
inflammation—blunted insulin suppression of lipolysis, which stems from adipocyte
hypertrophy.
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CHAPTER 6: SUMMARY AND CONCLUSIONS
6.1 Summary
Studies have suggested that defects in the ability to switch substrate oxidation
from fat to carbohydrate during insulin stimulation might contribute to development of
obesity and/or the metabolic sequelae of obesity (173). Metabolism involves the
adaptation to both the supply and demand of energy, and this adaptability requires ‘a
clear capacity to utilize lipid and carbohydrate fuels and to transition between them’
(123). In the healthy state, this transitioning between substrates is termed ‘metabolic
flexibility’. However, as it always is according to the laws of the universe, this state of
flexibility has a counterpart characterized by the body’s inability to switch substrate
utilization under appropriate conditions. This state is termed ‘metabolic inflexibility’.
Increasing evidence points to metabolic inflexibility as a key dysfunction of the cluster of
disease states that contribute to the metabolic syndrome, such as Type 2 diabetes. Two
main features of metabolic inflexibility are: (1) failure of skeletal muscle to
appropriately switch between the use of lipid in the fasting state and use of carbohydrate
upon insulin stimulation and (2) an impaired transition from fatty acid efflux to storage in
response to a meal. The reduced ability to metabolize fuel, such as oxidative
phosphorylation in the electron transport chain in skeletal muscle, is indicated by reduced
mitochondrial size and function, and it is characteristic of metabolic inflexibility (70;
123).
Our studies on the effects of an acute high fat diet (HFD) in a population of young
healthy males and mice demonstrated that substrate switching in skeletal muscle occurs
via classic endocrine/physiologic systems, as well as at the transcriptional level.
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Importantly, there were no changes in fasting glucose, insulin and free fatty acids after
the diet intervention, fatty acid oxidation did increase as measured by a decrease in
respiratory quotient (RQ). Using oligonucleotide microarray technology, we found that
about 300 genes were regulated by the three-day high fat diet in the skeletal muscle of
healthy young men. The first part of the microarray analysis, along with quantitative real
time RT-PCR, revealed a downregulation of OXPHOS genes after the HFD, as well as
transcription factors and cofactors involved in mitochondrial biogenesis. Additionally,
we observed that the reductions in the expression of genes involved in oxidative
phosphorylation and mitochondrial biogenesis were recapitulated in an animal model of
dietary-induced obesity and insulin resistance (134) and were of a much greater
magnitude in mice as compared to man.
In the second part of the microarray analysis, we expanded the investigation of the
effects of an acute high fat/low carbohydrate diet (HF/LCD) to the transcriptional
responses for other metabolic systems such as carbohydrate oxidation and storage, as
well as fatty acid oxidation. Muscle cells adjust the fuels they oxidize and match
substrate supply to demand. Fuel selection shifts toward the oxidation of fatty acids and
reduces the oxidation of glucose at the transcriptional level. A positive carbohydrate
balance was observed at the end of the three-day HF/LCD in the cohort of the healthy
young males, indicating a decrease in glucose oxidation. We also observed a decrease in
the messenger RNA levels of a number of genes involved in the oxidative, as well as
non-oxidative, glucose metabolism. Furthermore, the analogous murine experiment
showed a similar effect (albeit with a greater magnitude of change).
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Increased free fatty acid (FFA) levels are pivotal in complex disease states such as
Type 2 diabetes (T2D). It has recently been shown in obesity and other complex disease
states that there exists a resistance to suppression of lipolysis by insulin. This trait is
correlated with intraabdominal fat mass; furthermore, the impaired insulin suppression of
lipolysis leads to an increase in FFA availability at the liver and muscle. Leanness,
insulin sensitivity and fat cell size determine metabolic flexibility, and are subsequently
related to fasting free fatty acid (FFA) levels, as well as FFAs upon insulin infusion. Our
experiments revealed impaired insulin suppression of free fatty acids in a cohort of
healthy young men during a euglycemic-hyperinsulinemic clamp (EHC). Fat cell size
was positively correlated with fasting and insulin-suppressed FFAs, as well as expression
of macrophage markers and chemokines. Gene expression of macrophage markers
(CD68 and MAC-2) and chemokines (MCP-1 and MIP-1α) was positively correlated
with insulin-suppressed FFAs. Even more striking was that the expression of both the
macrophage markers and the chemokines was coordinately increased. One novel aspect
of this work was the negative correlation between insulin-suppressed FFAs and glucose
disposal rate (GDR), as well as fat cell size, chemokines and markers of macrophage
content. Interestingly, we observed a consistent negative correlation between “metabolic
flexibility” as measured by the change in respiratory quotient (RQ) and several adipose
tissue parameters such as percent body fat, fat cell size, insulin suppression of FFAs and
expression of chemokines and macrophage markers. Not only did we demonstrate the
expected relationships among adipocyte hypertrophy and glucose disposal, but we
revealed a consequence of adipocyte hypertrophy, increased expression of macrophage
markers and chemokines and subsequent impaired insulin suppression of lipolysis.
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6.2 Conclusions
The link between obesity and insulin resistance has been recognized for many
years. In the past several years, evidence that a disturbance in muscle lipid oxidative
capacity results in the accumulation of the lipid intermediates that interfere with insulin
signaling and ultimately inhibit insulin-mediated glucose uptake and subsequent
metabolism. Underlying mechanisms for disturbed fatty acid handling may relate to
impaired adipose tissue lipolysis and a reduced ability to oxidize fat. Many of these
abnormalities have been reported both in the obese and Type 2 diabetics (174-176).
Increased free fatty acid (FFA) flux from adipose tissue to non-adipose tissue is at the
heart of many metabolic disturbances characteristic of insulin resistance and Type 2
diabetes.
It has been purported that high fat diets and/or high fat flux through the
mitochondria reduce the expression of nuclear genes encoding mitochondrial proteins and
transcription factors involved in mitochondrial biogenesis. Our data support this
hypothesis. Previous studies suggest a link between the downregulation of PGC1 and the
dysregulation of OXPHOS genes. Our results are consistent with this sequence of events,
and indeed three of our OXPHOS genes were also present in analyses by Patti and
Mootha (83; 84). We also move our view upstream, beyond the relationship between
PGC1 and OXPHOS genes. We showed an increased fatty acid flux through the
mitochondria decreases PGC1 expression and is associated with a downregulation of
expression of genes involved in oxidative phosphorylation. Our studies support the novel
hypothesis that high fat diets explain the reduction in oxidative capacity that is seen in
aging, obesity, insulin resistance and Type 2 diabetes.
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The acute effects of fatty acids on glucose metabolism and storage have been
shown enzymatically; however, our studies supplement these effects by demonstrating a
downregulation of genes involved in glucose oxidation and storage when fat intake is
increased and carbohydrate intake is decreased. Therefore, we expand the view of the
‘glucose-fatty acid cycle’ beyond enzymatic activity to the transcriptional level. Overall,
our identification of multiple regulated genes within the same pathway by a high fat/low
carbohydrate diet is novel.
Adipose tissue in obesity becomes noncompliant to suppression of fat
mobilization, i.e. lipolysis, by insulin, and also to the normal insulin-stimulated fat
storage by activation of lipoprotein lipase. The net effect is “full” adipocytes that are
unable to store more fat; thus, in the post-prandial state after a meal, there is an excess
flux of lipid that would normally have been absorbed by the adipose tissue. This
situation leads to fat deposition in other tissues. Accumulation of triacylglycerol in
skeletal muscle and in liver is associated with insulin resistance. Furthermore, this
increase in fat flux leads to ‘metabolic inflexibility’ in whereby the skeletal muscle is
unable to switch substrates from fat to carbohydrate. The link between adipose tissue and
insulin resistance and metabolic flexibility emphasizes the important role of adipose
tissue in buffering the daily influx of dietary fat entering the circulation and preventing
excessive exposure of other tissues to this influx. Our studies have demonstrated a
physiological relationship among adipocyte hypertrophy, impaired insulin suppression of
adipose tissue lipolysis and glucose disposal in skeletal muscle. We also revealed at the
transcriptional level an increase in macrophage markers and chemokines. These data
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suggest an infiltration of macrophages and chemotaxis leads to the state of inflammation
present in obesity and its related metabolic disorders, such as metabolic inflexibility.
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APPENDIX A: SUPPLEMENTAL TABLES

Gene
NDUFB3
NDUFB5
NDUFV1
NDUFS1
SDHB
SLC25A12
18S
CYC1
SURF1
PGC1α
PGC1β
TFAM
NRF1
RPLP0
mmNDUFB3
mmNDUFB5
mmSLC25A12
mmSDHB
mmCYC1
mmSURF1
mmPGC1α
mmPGC1β
mmCOXII
mmUCP2
mmCycB

Accession
number
NM_002491
NM_002492
NM_007103
NM_005006
NM_003000
NM_003705
NM_000979
NM_001916
NM_003172
NM_015062
NM_133263
NM_009360
NM_005011
NM_001002
NM_025597
NM_025316
NM_172436
NM_023374
NM_025567
NM_013677
NM_008904
NM_133249
NC_005089
NM_011671
NM_011149

Forward primer

Probe

Reverse primer

TCAGATTGCTGTCAGACATGG
TTCGACACAGTGGAGACCAT
CTGATCCCCAAGTCTGTGTGTGAGA
GAATGTGATCTGCAGGACCAGTC
AAATGTGGCCCCATGGTATTG
AGCACTCTAGCTGGCACAAGGAA
GATATGCTCATGTGGTGTTGA
TGGCCCCTCCCATCTACAC
CCTATGTGGTCACTCCCTTCCA
AGGTGAAAGTGTAATACTGTTGGTTGA
CAGCCACTCGAAGGAACTTCA
CCCAGATGCAAAAACTACAGAACTAA
CGTTGCCCAAGTGAATTATTCTG
CCATTCTATCATCAACGGGTACAA
TGGCCATGGTAAAATGGAACT
GCATCCGATATCAAGATGGATCG
CACCACAGGACCGAGAGTCA
CCCAGGAGGGCAAGCAA
CAGCTACCCATGGTCTCATCGT
AAGTGAATCCTGAGACCAGACAGA
CATTTGATGCACTGACAGATGGA
AGGAAGCGGCGGGAAA
TTTTCAGGCTTCACCCTAGATGA
GCGTTCTGGGTACCATCCTAAC
GGTGGAGAGCACCAAGACAGA

Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
AGAGTTTGACGATGGCACCCCAGCTA
TGGTGACTCCCAGGTCGGTGCA
TGCTGAAGAGGGAAAGTGAGCGATTAGTTGA
CTGAACACGGCCCTCTGCTCTCACA
CGCAGTCACAACACTTACAAGCCAAAC
TTGTTCCACCTCTCCATCAGCCA
TCTCCACAGACAAGGCCAGGACTCG
CAGATTACAGACAGTGGAAAATTGAAGGGACG
CTGAAAAGAACTACGAGAAAACCCTGGCTATCCT
TGCTTCAGGACCTGGGACTTTTCGG
AGTATCTGCAGTCCATCGAGGACCGG
TCCGAATGCTGGTGTGGTCCAAGGA
AGGCCAGGTTCTGGGAGAAGTAGACC
CCGTGACCACTGACAACGAGGCC
AGAGATTTCGAATGTATACCACACGGCCTTCA
CATGAGCAAAAGCCCACTTCGCCA
CGCACTGAGGGTCCACGCAGC
ATCCTTCAGTGGCTTGTCCCGGCT

TGGTGTCCCTTCTATCTTCCA
TTCAGCTTGACCAATGAATACA
GATGTCCGTCGAGCGGTCCAT
GTCTTTACCAATGGCCCAATGT
AGAGCCACAGATGCCTTCTCTG
AGTCAAGCGCCCTGAAGCATTATAT
ACGTTCCACCTCATCCTCA
ATCCTTGGCTATCTGGGACATG
TGGGAACGAACCCTCTATTTACC
CATGTAGAATTGGCAGGTGGAA
CGGATGCTTGGCGTTCTG
TCCGCCCTATAAGCATCTTGA
CCCTGTAACGTGGCCCAAT
AGCAAGTGGGAAGGTGTAATCC
AAGCTTCTTCTGCACCGTTTCT
CTTTAACCGTAACTCAGCCTTTTCA
GGCTTTGGCACCCTTGTACA
GTACAGCCCGTCCAGCTTCT
CACCTGCTTGTATACCTGGAAACC
TGTGAGCCTCACTATGCCAACT
CCGTCAGGCATGGAGGAA
CTACAATCTCACCGAACACCTCAA
GAAGAATGTTATGTTTACTCCTACGAATATG
GCGACCAGCCCATTGTAGA
GCCGGAGTCGACAATGATG

A.1 Oligonucleotide sequences for primer/probe sets used for qRT-PCR. For all assays performed using SYBR Green I detection,
18S was used as the internal control, and for all assays performed using Taqman primers and probe, RPLP0, which is the human
equivalent of the murine gene 36B4, was used as the internal control. Cyclophilin B was used as the internal control for all murine
assays. NDUFB3, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3; NDUFB5, NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 5; NDUFV1, NADH dehydrogenase (ubiquinone) flavoprotein 1; NDUFS1, NADH dehydrogenase (ubiquinone) Fe-S
protein 1); SDHB, succinate dehydrogenase complex, subunit B; SLC25A12, solute carrier family 25 (mitochondrial carrier); 18S,
18S ribosomal RNA; CYC1, cytochrome c-1; SURF1, surfeit 1; PGC1α, peroxisome proliferative activated receptor, gamma,
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coactivator 1, alpha; PGC1β, peroxisome proliferative activated receptor, gamma, coactivator 1, beta; TFAM, transcription factor A,
mitochondrial; NRF1, nuclear respiratory factor-1; RPLP0, ribosomal protein, large, P0; mm, mus musculus; mmNDUFB3, NADH
dehydrogenase (ubiquinone) 1 beta subcomplex, 3; mmNDUFB5, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5;
mmSLC25A12, solute carrier family 25 (mitochondrial carrier); mmSDHB, succinate dehydrogenase complex, subunit B;
mmCYC1, cytochrome c-1; mmSURF1, surfeit 1; mmPGC1α, peroxisome proliferative activated receptor, gamma, coactivator 1,
alpha; mmPGC1β, peroxisome proliferative activated receptor, gamma, coactivator 1, beta; mmCOXII, cytochrome c oxidase II,
mitochondrial; mmUCP2, uncoupling protein 2; mmCycB, peptidylprolyl isomerase B (cyclophilin B).
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CLUSTER

ACCESSION

GENE DESCRIPTION

FOLD CHANGE

DIRECTION

FUNCTION

BONFERONNI PVALUE

1

AB028968

Homo sapiens mRNA for KIAA1045 protein, partial cds

1.5

down

biological process unknown

0.002999056

1

AB037743

Homo sapiens mRNA for KIAA1322 protein, partial cds

1.4

down

developmental processes

0.003082866

1

AB039903

Homo sapiens ifp1 mRNA for interferon-responsive finger protein 1 long form, complete cds

2

down

pathogenesis

0.000120886

1

AB046796

Homo sapiens mRNA for KIAA1576 protein, partial cds

1.4

down

ethanol oxidation

0.000091228

1

AF052087

Homo sapiens clone 23604 mRNA sequence

1.1

down

DNA packaging

3.34674E-06

1

AF060169

Homo sapiens AS11 protein mRNA, partial cds

1.8

down

transcription regulation

0.001436171

1

AF086156

Homo sapiens full length insert cDNA clone ZB55H12

1.1

down

biological process unknown

0.002373667

1

AF086350

Homo sapiens full length insert cDNA clone ZD62G08

2.2

down

biological process unknown

0.008001914

1

AF090102

Homo sapiens clone IMAGE 21785

2.1

down

biological process unknown

0.002811766

1

AK000032

Homo sapiens cDNA FLJ20025 fis, clone ADSE01840

1.8

down

biological process unknown

0.00025246

1

AK000789

Homo sapiens cDNA FLJ20782 fis, clone COL03841

2.6

down

biological process unknown

1.42117E-09

1

AK021462

Homo sapiens cDNA FLJ11400 fis, clone HEMBA1000673

2.4

down

biological process unknown

1.37972E-05

1

AK022297

Homo sapiens cDNA FLJ12235 fis, clone MAMMA1001243

1.7

down

biological process unknown

0.000513922

1

AK026037

Homo sapiens cDNA: FLJ22384 fis, clone HRC07594

1.4

down

biological process unknown

0.004993469

1

AL117653

Homo sapiens mRNA; cDNA DKFZp586C0224 (from clone DKFZp586C0224)

2.2

down

biological process unknown

0.000065843

1

AL137363

Homo sapiens mRNA; cDNA DKFZp434D1026 (from clone DKFZp434D1026)

1.4

down

biological process unknown

0.003665174

1

AL137597

Homo sapiens mRNA; cDNA DKFZp434B2411 (from clone DKFZp434B2411)

2.2

down

biological process unknown

0.00010901

1

AL157476

Homo sapiens mRNA; cDNA DKFZp761C082 (from clone DKFZp761C082)

1.7

down

cell adhesion

0.008059978

1

D87292

Homo sapiens mRNA for rhodanese, complete cds

1.9

down

cyanate catabolism

0.00610911

1

L19362

Human (clone xip1) mRNA sequence

1.5

down

biological process unknown

0.000444252

1

NM_000155

Homo sapiens galactose-1-phosphate uridylyltransferase (GALT) mRNA

1.6

down

galactose metabolism

0.009046843

1

NM_000476

Homo sapiens adenylate kinase 1 (AK1), nuclear gene encoding mitochondrial protein, mRNA

1.5

down

nucleic acid metabolism

0.000990824

1

NM_000532

H.sapiens propionyl Coenzyme A carboxylase, beta polypeptide (PCCB), mRNA

1.6

down

fatty acid catabolism

2.98029E-06

1

NM_000666

Homo sapiens aminoacylase 1 (ACY1), mRNA

1.6

down

proteolysis and peptidolysis

0.000398322

1

NM_001297

Homo sapiens cyclic nucleotide gated channel beta 1 (CNGB1) mRNA, and translated products

1.7

down

vision

2.01462E-09

1

NM_001412

Homo sapiens eukaryotic translation initiation factor 1A (EIF1A) mRNA

2

down

protein synthesis initiation

0.001449064

1

NM_002487

Homo sapiens necdin (mouse) homolog (NDN) mRNA

1.2

down

neurogenesis

0.001234221

1

NM_002491

Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3 (12kD, B12) (NDUFB3) mRNA

1.4

down

complex I (NADH to ubiquinone)

0.007275987

1

NM_003974

Homo sapiens docking protein 2, 56kD (DOK2) mRNA

1.4

down

signal transduction (cell surface receptor)

0.005136911

1

NM_004236

Homo sapiens thyroid receptor interacting protein 15 (TRIP15) mRNA

1.9

down

signal transduction

0.00960494

1

NM_007126

Homo sapiens valosin-containing protein (VCP), mRNA

2

down

intracellular protein traffic

0.000413305

1

NM_014056

Homo sapiens DKFZP564K247 protein (DKFZP564K247), mRNA

1.7

down

mitochondrial processing

1.14425E-07

1

NM_016417

Homo sapiens clone FLB4739 (LOC51218), mRNA

1.5

down

biological process unknown

0.001473864

1

NM_016599

Homo sapiens muscle-specific protein (LOC51778), mRNA

2.1

down

biological process unknown

0.000000

1

X78938

H.sapiens SRI mRNA

1.6

down

biological process unknown

0.00688159

1

AL049471

Homo sapiens mRNA; cDNA DKFZp586N012 (from clone DKFZp586N012)

1.7

up

biological process unknown

2.22666E-06

1

L08902

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

9.4576E-08

1

L09070

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L09071

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L09078

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

9.4576E-08

1

L09080

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L09081

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L09086

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L09089

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

9.4576E-08

1

L09092

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L09095

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L09097

Homo sapiens mRNA fragment

1.8

up

proteolysis and peptidolysis

9.4576E-08

1

L09098

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

9.4576E-08

1

L09099

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L09100

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L09102

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L10140

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L10141

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

99

1

L10146

Homo sapiens mRNA fragment

1.8

up

blood coagulation

9.4576E-08

1

L10147

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L10148

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L10151

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

9.4576E-08

1

L23867

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

L23869

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

L23870

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

L43345

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

L43347

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

L43349

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

L43350

Homo sapiens mRNA fragment

1.8

up

biological process unknown

9.4576E-08

1

NM_000067

Homo sapiens carbonic anhydrase II (CA2) mRNA

1

up

protein targeting

0.002923499

1

NM_000954

Homo sapiens prostaglandin D2 synthase (21kD, brain) (PTGDS), mRNA

1.9

up

prostaglandin metabolism

4.78094E-06

1

NM_001492

Homo sapiens growth differentiation factor 1 (GDF1), mRNA

1.4

up

membrane targeting

3.26237E-07

1

NM_001963

Homo sapiens epidermal growth factor (beta-urogastrone) (EGF) mRNA

1.7

up

signal transduction

0.001798554

1

NM_003234

Homo sapiens transferrin receptor (p90, CD71) (TFRC) mRNA

1.5

up

iron transport

1

NM_005655

Homo sapiens TGFB inducible early growth response (TIEG), mRNA

1.9

up

cell proliferation

1

NM_016485

Homo sapiens hypothetical protein (HSPC228), mRNA

1.6

up

cell wall integrity

1.50129E-09

1

NM_017659

Homo sapiens hypothetical protein FLJ20084 (FLJ20084), mRNA

1.3

up

protein modification

0.006886306

1

NM_018593

Homo sapiens hypothetical protein PRO0813 (PRO0813), mRNA

1.7

up

biological process unknown

0.000337473

1

U81380

Human interleukin-13 receptor soluble form mRNA, complete cds

1.2

up

signal transduction (cell surface receptor)

0.000180734

1
1

X04236
Z36789

Human small cellular 7 SK mRNA
H.sapiens (xs138) mRNA, 250bp

1.2
1.9

up
up

biological process unknown
blood coagulation

0.001137583
2.33058E-06

2

AF055030

Homo sapiens clone 24538 mRNA sequence

1.5

down

transcription regulation

0.005462657

2

AF070565

Homo sapiens clone 24425 mRNA sequence

2

down

biological process unknown

2.38024E-08

2

AF086264

Homo sapiens full length insert cDNA clone ZD43A10

1.1

down

biological process unknown

0.000105155

2

AF147426

Homo sapiens full length insert cDNA clone YP79H10

1.3

down

biological process unknown

3.36945E-09

2

AK001906

Homo sapiens cDNA FLJ11044 fis, clone PLACE1004451

1.4

down

biological process unknown

0.002560693

2

AK025657

Homo sapiens cDNA: FLJ22004 fis, clone HEP06871

2.1

down

sensory perception

3.78602E-08

2

AL049361

Homo sapiens mRNA; cDNA DKFZp566H243 (from clone DKFZp566H243)

1.6

down

biological process unknown

2.13573E-05

2

AL050148

Homo sapiens mRNA; cDNA DKFZp586G1520 (from clone DKFZp586G1520)

1.6

down

biological process unknown

9.92366E-05

2

AL390169

Homo sapiens mRNA; cDNA DKFZp547D064 (from clone DKFZp547D064)

1.8

down

biological process unknown

0.000091741

2

NM_000083

Homo sapiens chloride channel 1 , skeletal muscle (CLCN1), mRNA

1.8

down

chloride transport

2.58873E-07

2

NM_000717

Homo sapiens carbonic anhydrase IV (CA4), mRNA

1.5

down

protein targeting

0.0061872

2

NM_001829

Homo sapiens chloride channel 3 (CLCN3) mRNA

1.4

down

chloride transport

0.004788336

2

NM_003167

Homo sapiens sulfotransferase family 2A, dehydroepiandrosterone (DHEA) -preferring, member 1 (SULT2A1) mRNA

1.3

down

steroid metabolism

0.008640503

2

NM_003344

Homo sapiens ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) (UBE2H) mRNA

1.4

down

proteolysis and peptidolysis

6.68648E-06

2

NM_003665

Homo sapiens ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen) (FCN3), mRNA

1.6

down

opsinization

0.000932942

2

NM_004170

Homo sapiens solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter), member 1 (SLC1A1), mRNA

1.3

down

glutamate transport

0.000186263

2

NM_014709

Homo sapiens KIAA0570 gene product (KIAA0570), mRNA

1.2

down

spermatogenesis

0.000871745

2

NM_014752

Homo sapiens KIAA0102 gene product (KIAA0102), mRNA

1.2

down

steroid metabolism

0.00045674

2

NM_014845

Homo sapiens KIAA0274 gene product (KIAA0274), mRNA

1.6

down

synaptic vesicle endocytosis

4.30869E-09

2

NM_017781

Homo sapiens hypothetical protein FLJ20359 (FLJ20359), mRNA

1.4

down

electron transport

0.002432844

2

NM_018467

Homo sapiens uncharacterized hematopoietic stem/progenitor cells protein MDS032 (MDS032), mRNA

1.8

down

immune response

0.000685921

2

AB011152

Homo sapiens mRNA for KIAA0580 protein, partial cds

1.4

up

cytoskeleton integrity

2.58635E-05

2

AB018310

Homo sapiens mRNA for KIAA0767 protein, partial cds

1.4

up

steroid metabolism

0.000210553

2

AB033102

Homo sapiens mRNA for KIAA1276 protein, partial cds

1.5

up

muscle contraction

2.87647E-07

2

AF082657

Homo sapiens Era GTPase A protein (HERA-A) mRNA, partial cds

1.5

up

transport

0.00500205

2

AF085351

Homo sapiens ELISC-1 mRNA, partial cds

1.2

up

biological process unknown

7.24137E-09

2

AF291181

Homo sapiens LHX5 protein mRNA, complete cds

1.3

up

transcription regulation

0.00044144

2

AJ224166

Homo sapiens mRNA containing U19H snoRNA; mRNA 1

1.2

up

cell growth and maintenance

5.90463E-05

2

AK022872

Homo sapiens cDNA FLJ12810 fis, clone NT2RP2002464, weakly similar to DNA repair protein PSO2/SNM1

1.6

up

DNA repair

3.07146E-07

2

AK023610

Homo sapiens cDNA FLJ13548 fis, clone PLACE1007068

1.4

up

biological process unknown

0.005040947

2

AK023683

Homo sapiens cDNA FLJ13621 fis, clone PLACE1010954

1.1

up

cytoskeleton integrity

0.002260697

2

AK024927

Homo sapiens cDNA: FLJ21274 fis, clone COL01781

1.5

up

biological process unknown

0.003126244

100

0.009
1.3307E-09

2

AK026679

Homo sapiens cDNA: FLJ23026 fis, clone LNG01738

2.1

up

biological process unknown

2

AL161991

Homo sapiens mRNA; cDNA DKFZp761C169 (from clone DKFZp761C169); partial cds

1.4

up

biological process unknown

6.62599E-08

2

L08902

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

0.001922163

2

L09070

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L09071

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L09078

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

0.001922163

2

L09080

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L09081

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L09086

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L09089

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

0.001922163

2

L09092

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L09095

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L09097

Homo sapiens mRNA fragment

1.8

up

proteolysis and peptidolysis

0.001922163

2

L09098

Homo sapiens mRNA fragment

1.8

up

humoral defense mechanism

0.001922163

2

L09099

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L09100

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L09102

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L10140

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L10141

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L10146

Homo sapiens mRNA fragment

1.8

up

blood coagulation

0.001922163

2

L10147

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L10148

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L10151

Homo sapiens mRNA fragment

1.8

up

chymotrypsin

0.001922163

2

L23867

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

L23869

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

L23870

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

L25080

Homo sapiens GTP-binding protein (rhoA) mRNA, complete cds

1.6

up

cell growth and maintenance

0.002526602

2

L43345

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

L43347

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

L43349

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

L43350

Homo sapiens mRNA fragment

1.8

up

biological process unknown

0.001922163

2

M20699

Human terminal deoxynucleotidyltransferase gene, exon 7

1.4

up

DNA replication

5.20357E-09

2

M55536

Human glucose transporter pseudogene

1.4

up

biological process unknown

2

NM_000367

Homo sapiens thiopurine S-methyltransferase (TPMT) mRNA

1.3

up

nucleic acid metabolism

2

NM_001714

Homo sapiens Bicaudal D (Drosophila) homolog 1 (BICD1) mRNA

1.5

up

embryogenesis and morphogenesis

1.56169E-06

2

NM_002864

Homo sapiens pregnancy-zone protein (PZP) mRNA

1.6

up

intracellular protein traffic

0.005691476

2

NM_002907

Homo sapiens RecQ protein-like (DNA helicase Q1-like) (RECQL) mRNA

1.5

up

DNA repair

0.000516067

2

NM_003375

Homo sapiens voltage-dependent anion channel 2 (VDAC2), nuclear gene encoding mitochondrial protein, mRNA

1.5

up

anion transport

2.28422E-06

2

NM_004259

Homo sapiens RecQ protein 5 (RECQ5) mRNA

1.4

up

DNA repair

1.43416E-06

2

NM_005531

Homo sapiens interferon, gamma-inducible protein 16 (IFI16) mRNA

1.7

up

transcription regulation

9.65381E-07

2

NM_006598

Homo sapiens solute carrier family 12 (potassium/chloride transporters), member 7 (SLC12A7), mRNA

2.8

up

transport

0.000156565

2

NM_007016

Homo sapiens protein similar to E.coli yhdg and R. capsulatus nifR3 (PP35), mRNA

1.4

up

`de novo` pyrimidine biosynthesis

0.000204868

2

NM_014590

Homo sapiens endogenous retroviral family W, env(C7), member 1 (syncytin) (ERVWE1), mRNA

1.2

up

embryogenesis and morphogenesis

2.40867E-06

2

NM_014873

Homo sapiens KIAA0205 gene product (KIAA0205), mRNA

1.7

up

phosphatidic acid biosynthesis

0.003616239

2

NM_015975

Homo sapiens neuronal cell death-related protein (LOC51616), mRNA

1.5

up

nucleic acid metabolism

3.86252E-05

2

NM_016360

Homo sapiens clone HQ0477 PRO0477p (LOC51204), mRNA

1.5

up

nucleotide-excision repair

3.44637E-05

2

NM_018183

Homo sapiens hypothetical protein FLJ10701 (FLJ10701), mRNA

1

up

DNA repair

0.003742495

2

NM_020367

Homo sapiens MIB006 (C12orf6), mRNA

1.1

up

cytoskeleton integrity

0.000435746

2

U10511

Human clone 2D12 Cri-du-chat critical region mRNA, partial sequence

1.9

up

biological process unknown

1.57562E-06

2
2

X74804
X78712

H.sapiens D54 mRNA
H.sapiens mRNA for glycerol kinase testis specific 2

1.6
1.5

up
up

biological process unknown
glycerol metabolism

0.003756293
0.000155077

3

AF009265

Homo sapiens clone FB2C5 Cri-du-chat region mRNA

1.4

down

biological process unknown

0.000445326

3

AF088018

Homo sapiens full length insert cDNA clone YY88A05

1.3

down

biological process unknown

4.72428E-05

3

AF131855

Homo sapiens clone 25056 mRNA sequence

1.5

down

biological process unknown

2.84387E-07

3

AF147343

Homo sapiens full length insert cDNA clone YB31B05

1.9

down

biological process unknown

5.47705E-06

101

0.005879573

4.658E-12
0.000455608

3

AF147369

Homo sapiens full length insert cDNA clone YB64E02

1.4

down

biological process unknown

0.00341564

3

AK001228

Homo sapiens cDNA FLJ10366 fis, clone NT2RM2001420

1.8

down

biological process unknown

2.26217E-05

3

AK002109

Homo sapiens cDNA FLJ11247 fis, clone PLACE1008693

1.4

down

biological process unknown

0.001115375

3

AK002150

Homo sapiens cDNA FLJ11288 fis, clone PLACE1009607

1.8

down

biological process unknown

0.000234275

3

AK002173

Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102

1.4

down

biological process unknown

0.006648993

3

AK022850

Homo sapiens cDNA FLJ12788 fis, clone NT2RP2001946

1.4

down

biological process unknown

1.53982E-07

3

AK023600

Homo sapiens cDNA FLJ13538 fis, clone PLACE1006617

1.5

down

biological process unknown

0.008859778

3

AK026099

Homo sapiens cDNA: FLJ22446 fis, clone HRC09457

2.2

down

biological process unknown

0.009163995

3

AK026571

Homo sapiens cDNA: FLJ22918 fis, clone KAT06627

1.4

down

biological process unknown

0.002059913

3

AL049342

Homo sapiens mRNA; cDNA DKFZp566A193 (from clone DKFZp566A193)

1.5

down

biological process unknown

0.000592814

3

AL109715

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 430268

1.4

down

biological process unknown

0.000185708

3

AL109818

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 191017

1.3

down

biological process unknown

0.000423743

3

AL137313

Homo sapiens mRNA; cDNA DKFZp761M10121 (from clone DKFZp761M10121)

1.4

down

biological process unknown

0.007227646

3

AL137703

Homo sapiens mRNA; cDNA DKFZp564P1772 (from clone DKFZp564P1772)

1.2

down

DNA packaging

0.002187628

3

AL162065

Homo sapiens mRNA; cDNA DKFZp762K135 (from clone DKFZp762K135)

1.5

down

transcription regulation

0.000696087

3

AL359056

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 328974

1.3

down

biological process unknown

0.003624825

3

D28446

Human mRNA for cytokeratin 8, 5'UTR (sequence from the 5'cap to the start codon)

1.8

down

biological process unknown

0.004367359

3

L39924

Homo sapiens (clone HPL14E8) mRNA, partial EST

1.4

down

biological process unknown

2.23848E-05

3

NM_000143

Homo sapiens fumarate hydratase (FH) mRNA

1.8

down

fumarate metabolism

0.000064016

3

NM_002048

Homo sapiens growth arrest-specific 1 (GAS1) mRNA

1.7

down

cell cycle arrest

0.000240229

3

NM_002413

Homo sapiens microsomal glutathione S-transferase 2 (MGST2) mRNA, and translated products

1.7

down

leukotriene metabolism

0.000741744

3

NM_003705

Homo sapiens solute carrier family 25 (mitochondrial carrier, Aralar), member 12 (SLC25A12) mRNA

1.8

down

mitochondrial transport

4.58982E-09

3

NM_004837

Homo sapiens geranylgeranyl diphosphate synthase 1 (GGPS1), mRNA

1.4

down

lipid metabolism

0.001170041

3

NM_006550

Homo sapiens fibrinogen silencer binding protein (FSBP) mRNA

1.8

down

developmental processes

0.008701064

3

NM_014028

Homo sapiens HSPC019 protein (HSPC019), mRNA

1.2

down

biological process unknown

1.26357E-08

3

NM_014118

Homo sapiens PRO0159 protein (PRO0159), mRNA

1.9

down

biological process unknown

4.29652E-05

3

NM_014157

Homo sapiens HSPC065 protein (HSPC065), mRNA

1.4

down

biological process unknown

0.000726736

3

NM_018394

Homo sapiens hypothetical protein FLJ11342 (FLJ11342), mRNA

2

down

nitrogen metabolism

0.002850132

3

NM_019845

Homo sapiens candidate mediator of the p53-dependent G2 arrest (REPRIMO), mRNA

1.3

down

cell cycle arrest

0.005328642

3

U00960

Human clone KDBB1.2 (CAC)n/(GTG)n repeat-containing mRNA

1.6

down

biological process unknown

8.63988E-10

3

AB029396

Homo sapiens hu-GlcAT-P mRNA for glucuronyltransferase, complete cds

1.2

up

carbohydrate metabolism

0.005055305

3

AB037770

Homo sapiens mRNA for KIAA1349 protein, partial cds

1.3

up

transcription regulation

3.68379E-05

3

AB040672

Homo sapiens GalNAc-T9 mRNA for UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, complete cds

1.1

up

carbohydrate metabolism

2.60519E-06

3

AF052115

Homo sapiens clone 23688 mRNA sequence

1.3

up

biological process unknown

0.000309023

3

AF086535

Homo sapiens full length insert cDNA clone ZE07G05

1.7

up

biological process unknown

5.46007E-05

3

AF088035

Homo sapiens full length insert cDNA clone ZC26G04

1.5

up

biological process unknown

0.001835077

3

AF090920

Homo sapiens clone HQ0352 PRO0352 mRNA, partial cds

1.2

up

biological process unknown

0.001037299

3

AF147349

Homo sapiens full length insert cDNA clone YB40C09

1.1

up

biological process unknown

6.10882E-05

3

AF320908

Homo sapiens MAGE-D4 (MAGED4) mRNA, partial cds

1.4

up

neurogenesis

1.9466E-11

3

AK023060

Homo sapiens cDNA FLJ12998 fis, clone NT2RP3000267

1.6

up

energy pathways

0.000269399

3

AK024244

Homo sapiens cDNA FLJ14182 fis, clone NT2RP2004675

2.1

up

biological process unknown

1.01781E-07

3

AK025686

Homo sapiens cDNA: FLJ22033 fis, clone HEP08810, highly similar to HSU43374 Human normal keratinocyte mRNA

1.6

up

biological process unknown

0.000105142

3

AL049679

Human gene from PAC 97K10, chromosome X, similar to heparan-sulphate 6-sulfotransferase

1.3

up

heparin sulfate biosynthesis

1.3547E-09

3

AL137519

Homo sapiens mRNA; cDNA DKFZp434A1518 (from clone DKFZp434A1518); partial cds

1.9

up

microtubule-based movement

3

D63487

Human mRNA for KIAA0153 gene, partial cds

1.2

up

cytoskeleton integrity

3

L19778

Homo sapiens histone H2A.1b mRNA, complete cds

1.8

up

nucleosome assembly

8.01858E-06

3

L23544

Human (clone z159) retinal mRNA

1.1

up

biological process unknown

1.68491E-08

3

NM_001075

Homo sapiens UDP glycosyltransferase 2 family, polypeptide B10 (UGT2B10) mRNA

1.9

up

metabolism

1.01363E-05

3

NM_001718

Homo sapiens bone morphogenetic protein 6 (BMP6) mRNA

1.1

up

cell growth and maintenance

0.004084709

3

NM_002232

Homo sapiens potassium voltage-gated channel, shaker-related subfamily, member 3 (KCNA3) mRNA

1.5

up

potassium transport

0.00010528

3

NM_002416

Homo sapiens monokine induced by gamma interferon (MIG), mRNA

1.2

up

immune response

0.003447458

3

NM_006332

Homo sapiens interferon, gamma-inducible protein 30 (IFI30) mRNA

1.7

up

immune response

8.38588E-06

3

NM_006581

Homo sapiens fucosyltransferase 9 (alpha (1,3) fucosyltransferase) (FUT9) mRNA

1.2

up

carbohydrate metabolism

0.002088679

3

NM_006782

Homo sapiens zinc-finger protein in MEN1 region (MCG4), mRNA

1.6

up

cell growth and maintenance

0.000808155

3

NM_006925

Homo sapiens splicing factor, arginine/serine-rich 5 (SFRS5), mRNA

1.4

up

mRNA processing

4.88143E-05
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3

NM_013363

Homo sapiens procollagen C-endopeptidase enhancer 2 (PCOLCE2), mRNA

1.5

up

cell growth and maintenance

0.00114394

3

NM_014470

Homo sapiens GTP-binding protein (RHO6), mRNA

1.7

up

cell growth and maintenance

0.001556582

3

NM_017721

Homo sapiens hypothetical protein FLJ20241 (FLJ20241), mRNA

1.5

up

cytoskeleton integrity

2.11999E-05

3
3

NM_017912
NM_018224

Homo sapiens hypothetical protein FLJ20637 (FLJ20637), mRNA
Homo sapiens hypothetical protein FLJ10803 (FLJ10803), mRNA

1.4
1.6

up
up

ubiquitination
biological process unknown

4.50622E-06
6.82061E-07

4

AF086084

Homo sapiens full length insert cDNA clone YZ84C01

1.3

down

biological process unknown

0.000937429

4

AK000165

Homo sapiens cDNA FLJ20158 fis, clone COL08935

1.2

down

biological process unknown

0.007709425

4

AK001125

Homo sapiens cDNA FLJ10263 fis, clone HEMBB1000991

1.3

down

biological process unknown

0.00420537

4

AK021722

Homo sapiens cDNA FLJ11660 fis, clone HEMBA1004610

1.5

down

biological process unknown

0.00033026

4

AK023224

Homo sapiens cDNA FLJ13162 fis, clone NT2RP3003625

1.4

down

biological process unknown

0.00060531

4

L07383

Homo sapiens E2 small nucleolar RNA

1.8

down

biological process unknown

0.000200539

4

NM_002133

Homo sapiens heme oxygenase (decycling) 1 (HMOX1), mRNA

2.8

down

C21-steroid hormone biosynthesis

1.74019E-07

4

NM_002563

Homo sapiens purinergic receptor P2Y, G-protein coupled, 1 (P2RY1) mRNA

1.2

down

G-protein signaling, activates PLC

0.001918707

4

NM_014664

Homo sapiens KIAA0615 gene product (KIAA0615), mRNA

1.6

down

proteolysis and peptidolysis

0.00172726

4

U00925

Human clone C4E 1.61 (CAC)n/(GTG)n repeat-containing mRNA

1.4

down

biological process unknown

2.82531E-06

4

U79249

Human clone 23839 mRNA sequence

2.2

down

biological process unknown

0.004528961

4

U80770

Human EST clone 251800 mariner transposon Hsmar1 sequence

1.7

down

chromatin binding

0.001639818

4

AF091033

Homo sapiens GTP-binding protein RAB19B (RAB19B) mRNA, partial cds

1.8

up

intracellular protein traffic

0.001388839

4

AK024067

Homo sapiens cDNA FLJ14005 fis, clone Y79AA1002361, similar to Rattus norvegicus mRNA for protein phosphatase 1

1.7

up

glycogen metabolism

2.59537E-10

4

AL137724

Homo sapiens mRNA; cDNA DKFZp434D1319 (from clone DKFZp434D1319); partial cds

1.3

up

cell growth and maintenance

0.000010435

4

NM_002871

Homo sapiens RAB interacting factor (RABIF) mRNA

1.5

up

non-selective vesicle transport

0.000179949

4

NM_004113

Homo sapiens fibroblast growth factor 12B (FGF12B) mRNA

1.6

up

signal transduction

0.004340852

4

NM_006765

Homo sapiens Putative prostate cancer tumor suppressor (N33), mRNA

1.1

up

protein-nucleus import

9.01884E-05

4

NM_012200

Homo sapiens beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) (B3GAT3), mRNA

1.5

up

carbohydrate metabolism

0.000264031

4

NM_016109

Homo sapiens PPAR(gamma) angiopoietin related protein (PGAR), mRNA

1.3

up

cell growth and maintenance

1.86227E-08

4

NM_017737

Homo sapiens hypothetical protein FLJ20275 (FLJ20275), mRNA

1.6

up

cell growth and maintenance

0.009220201

4
4

U79242
U92017

Human clone 23560 mRNA sequence
Human clone 199288 defective mariner transposon Hsmar2 mRNA sequence

1.7
1.4

up
up

biological process unknown
biological process unknown

0.000772738
9.44859E-07

5

AF084362

Homo sapiens lipoate-protein ligase B mRNA, partial cds

1.3

down

cell cycle

0.000224514

5

AF086220

Homo sapiens full length insert cDNA clone ZC66B10

1.6

down

biological process unknown

4.01705E-05

5

AF147395

Homo sapiens full length insert cDNA clone YI62C12

1.5

down

biological process unknown

0.001884459

5

AF207831

Homo sapiens guanine nucleotide exchange factor (ARHGEF6) mRNA, 5' UTR and partial cds

2.1

down

biological process unknown

1.18416E-09

5

AK026728

Homo sapiens cDNA: FLJ23075 fis, clone LNG05768

1.6

down

biological process unknown

0.001440961

5

AL050182

Homo sapiens mRNA; cDNA DKFZp586A1923 (from clone DKFZp586A1923)

1.9

down

microtubule-based process

0.004033682

5

AL137511

Homo sapiens mRNA; cDNA DKFZp761M222 (from clone DKFZp761M222)

1.3

down

electron transport

0.001218442

5

AL137631

Homo sapiens mRNA; cDNA DKFZp434B205 (from clone DKFZp434B205); partial cds

1.6

down

intracellular protein traffic

0.009583668

5

M11948

Human promyelocytic leukemia cell mRNA, clones pHH58 and pHH81

1.5

down

biological process unknown

0.000240291

5

NM_000016

H.sapiens acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM), mRNA

2.3

down

fatty acid beta-oxidation

0.00124041

5

NM_000925

Homo sapiens pyruvate dehydrogenase (lipoamide) beta (PDHB) mRNA

1.7

down

glucose metabolism

0.000125179

5

NM_001232

Homo sapiens calsequestrin 2, cardiac muscle (CASQ2), mRNA

1.8

down

striated muscle contraction

3.21972E-10

5

NM_001359

Homo sapiens 2,4-dienoyl CoA reductase 1, mitochondrial (DECR1), mRNA

1.8

down

fatty acid beta-oxidation

0.001979939

5

NM_001995

Homo sapiens fatty-acid-Coenzyme A ligase, long-chain 1 (FACL1), nuclear gene encoding mitochondrial protein, mRNA

2

down

fatty acid metabolism

6E-15

5

NM_002079

Homo sapiens glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) (GOT1) mRNA

1.7

down

aspartate catabolism

0.004712809

5

NM_002103

Homo sapiens glycogen synthase 1 (muscle) (GYS1) mRNA

1.7

down

glycogen metabolism

0.00081699

5

NM_002218

Homo sapiens inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4) mRNA

1.2

down

proteolysis and peptidolysis

0.003586815

5

NM_002492

Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 (16kD, SGDH) (NDUFB5) mRNA

1.9

down

complex I (NADH to ubiquinone)

2.09703E-05

5

NM_002493

Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17) (NDUFB6) mRNA

1.4

down

complex I (NADH to ubiquinone)

0.000392787

5

NM_002756

Homo sapiens mitogen-activated protein kinase kinase 3 (MAP2K3), mRNA

2

down

signal transduction

5.21806E-08

5

NM_003000

Homo sapiens succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB), mRNA

2.4

down

electron transport

0.000318155

5

NM_003754

Homo sapiens eukaryotic translation initiation factor 3, subunit 5 (epsilon, 47kD) (EIF3S5) mRNA

1.8

down

translational regulation, initiation

0.004751168

5

NM_005006

H.sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 1 (75kD) (NADH-coenzyme Q reductase) (NDUFS1) mRNA

2.4

down

complex I (NADH to ubiquinone)

0.001563059

5

NM_006759

Homo sapiens UDP-glucose pyrophosphorylase 2 (UGP2), mRNA

2

down

UDP-glucose metabolism

1.03084E-07

5

NM_007079

Homo sapiens protein tyrosine phosphatase type IVA, member 3 (PTP4A3), mRNA

1.7

down

DNA replication

1.15352E-05

5

NM_007103

Homo sapiens NADH dehydrogenase (ubiquinone) flavoprotein 1 (51kD) (NDUFV1), mRNA

1.9

down

energy pathways

0.000114478

5

NM_015831

Homo sapiens acetylcholinesterase (YT blood group) (ACHE), transcript variant E4-E5, mRNA

1.9

down

synaptic transmission

4.33511E-07
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5

NM_018464

Homo sapiens uncharacterized hematopoietic stem/progenitor cells protein MDS029 (MDS029), mRNA

1.9

down

microtubule-based process

3.07654E-10

5

NM_018533

Homo sapiens hypothetical protein PRO2706 (PRO2706), mRNA

1.8

down

biological process unknown

9.05355E-07

5

S74678

heterogeneous nuclear ribonucleoprotein complex K [human, mRNA, 2302 nt]

2.2

down

RNA processing

2.462E-12

5

U00942

Human clone A9A2BR17 (CAC)n/(GTG)n repeat-containing mRNA

1.7

down

biological process unknown

0.00089146

5

U56725

Human heat shock protein mRNA, complete cds

1.4

down

spermatid development

0.000542513

5

X03168

Human mRNA for S-protein

1.9

down

cell adhesion

0.001129344

5

Y12235

H.sapiens mRNA for fructose-1,6-biphosphatase, alternative 5'UTR

1.4

down

biological process unknown

0.001089767

5

AJ001904

Homo sapiens cDNA selection product, DCR1-24.0

1.2

up

biological process unknown

0.001378771

5

AK022090

Homo sapiens cDNA FLJ12028 fis, clone HEMBB1001850

1.4

up

biological process unknown

0.002103195

5

AK022282

Homo sapiens cDNA FLJ12220 fis, clone MAMMA1001082

1.9

up

biological process unknown

1.02208E-08

5

AK022343

Homo sapiens cDNA FLJ12281 fis, clone MAMMA1001745

1.4

up

biological process unknown

0.002352396

5

AK024532

Homo sapiens cDNA: FLJ20879 fis, clone ADKA03124

1.1

up

biological process unknown

0.007801208

5

D16875

Human HepG2 3' region cDNA, clone hmd1f06

1.4

up

biological process unknown

0.000715273

5

NM_000596

Homo sapiens insulin-like growth factor binding protein 1 (IGFBP1), mRNA

1.9

up

signal transduction

2.1353E-11

5

NM_001647

Homo sapiens apolipoprotein D (APOD) mRNA

1.7

up

transport

0.002302229

5

NM_002612

Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4) mRNA

1.7

up

glucose metabolism

0.000173786

5

NM_003492

Homo sapiens ITBA1 gene (ITBA1), mRNA

1.8

up

biological process unknown

0.000131711

5

NM_004566

Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) mRNA

3.3

up

fructose metabolism

5

NM_004906

Homo sapiens gene predicted from cDNA with a complete coding sequence (KIAA0105) mRNA

1.8

up

cell cycle

7.90062E-08

5

NM_005920

Homo sapiens MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D) (MEF2D) mRNA

1.4

up

transcription regulation

0.009663229

5

NM_020162

Homo sapiens hypothetical protein DKFZp762F2011 (DKFZp762F2011), mRNA

2.1

up

developmental processes

6.83262E-07

5

NM_020193

Homo sapiens GL002 protein (GL002), mRNA

1.9

up

cytoskeleton integrity

5.20558E-05

5

U21072

Human tandem repeat region from facioscapulohumeral muscular dystrophy-associated mRNA clone cDNAdelta4

1.3

up

biological process unknown

1.35132E-06

5

U52832

Homo sapiens Cri-du-chat region mRNA, clone CSC3

1.6

up

biological process unknown

0.000895676

2E-14

Appendix A.2 Microarray low laser hit list (p < 0.01). By microarray analysis, 298 genes were up- or downregulated
after a HFD. Of those 298, 6 are known to be involved in oxidative phosphorylation or mitochondrial function.
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Gene
PDK4
PFKFB3
GYS1
GALT
RPLP0
PDHB
MAP2K3
UGP2
18S
mmPDK4
mmPFKFB3
mmGALT
mmGYS1
mmCycB

Accession
number
NM_002612
NM_004566
NM_002103
NM_000155
NM_001002
NM_000925
NM_002756
NM_006759
NM_022551
NM_013743
NM_133232
NM_016658
NM_030678
NM_011149

Forward primer

Probe

Reverse primer

TTTCCAGACCAACCAATTCACA
ACTACTAGAGAGAGGAGACACATGATCCT
GAGAACGCAGTGCTCTTCGAA
ACGCCGCAGCAGCAA
CCATTCTATCATCAACGGGTACAA
GAAGGAGGCTGGCCACAGT
CTACATGGCCCCTGAGAGGAT
AATCAACCCACCCAATGGAA
GATATGCTCATGTGGTGTTGA
TTCCATGAGAAGAGCCCAGAA
TGCAGAGGAGATGCCATACCT
GCCATGATGGGCTGTTCTAAC
CCGGCTTTGGCTGCTTTA
GGTGGAGAGCACCAAGACAGA

AGCATATGATGGAGGTGAGAAGGAACATACACG
AACGCCTTAAAGTCATTTTCTTTGGCAAAATG
TGCCACCCACCTTGTTAGCCACCT
TGCTGATGGTCGTTTGCCCGG
TCTCCACAGACAAGGCCAGGACTCG
Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
Sybr Green I detection
CCCTGTCAGAGTTTGTAGACACGCTGGTCA
TCAGTTTCAGGACAGTGTGGAGCGGA
TGCTAGCCCAAACCTGGCAGTGG
TAAATGCCGTAAGCTGAGGGATCTGCGAT
ATCCTTCAGTGGCTTGTCCCGGCT

CGCATTGCATTCTTAAATAGTTCAA
CGCACACCGACTCGATGA
TCGTCTGCAGCACCGTGTAG
CATCCTGCAGCGGGTTGTA
AGCAAGTGGGAAGGTGTAATCC
TTGAACGCAGGACCTTCCAT
TCCAGACG TCGGACTTGACA
GTGAGTGTCCCGCCCTTTAC
ACGTTCCACCTCATCCTCA
GCCATTGTAGGGACCACATTATG
ACCCGGCACCCATATGC
GGGCGATATCTGGCAGGAA
CGGAACCTCCGATCCAGAAT
GCCGGAGTCGACAATGATG

Appendix A.3 Oligonucleotide sequences for primer/probe sets used for qRT-PCR. For all assays performed using Taqman
primers and probe, RPLP0, which is the human equivalent of the murine gene 36B4, was used as the internal control. For all assays
performed using SYBR Green I detection, 18S was used. Cyclophilin B was used as the internal control for all murine assays. PDK4,
pyruvate dehydrogenase kinase, isoenzyme 4; PFKFB3, fructose-2,6-biphosphatase 3; GYS1, glycogen synthase 1 (muscle); GALT,
galactose-1-phosphate uridyltransferase; RPLP0, ribosomal protein, large, P0; PDHB, pyruvate dehydrogenase (lipoamide) beta;
MAP2K3, mitogen-activated protein kinase kinase 3; UGP2, UDP-glucose pyrophosphorylase 2; 18S, ribosomal protein S18; mm,
mus musculus; mmPDK4, pyruvate dehydrogenase kinase, isoenzyme 4; mmPFKFB3, fructose-2,6-biphosphatase 3; mmGALT,
galactose-1-phosphate uridylyltransferase; mmGYS1, glycogen synthase 1 (muscle); mmCycB, peptidylprolyl isomerase B
(cyclophilin B).
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GENE DESCRIPTION

FOLD CHANGE

DIRECTION

FUNCTION

BONFERONNI PVALUE

CLUSTER

ACCESSION

1

AF075006

Homo sapiens full length insert cDNA YH98F07

2.2

down

biological process unknown

0.018577505

1

AJ227908

Homo sapiens partial mRNA; ID ED70-2A

2.9

down

biological process unknown

0.011717709

1

AK025950

Homo sapiens cDNA: FLJ22297 fis, clone HRC04521

1.8

down

cell cycle

0.048899404

1

AK026675

Homo sapiens cDNA: FLJ23022 fis, clone LNG01117

2.3

down

biological process unknown

0.035757495

Homo sapiens mRNA; cDNA DKFZp762H185 (from clone DKFZp762H185)

1.8

down

biological process unknown

0.028866444

Homo sapiens protease, serine, 15 (PRSS15), mRNA

2.0

down

proteolysis and peptidolysis

0.025259937

1

AL359586

1

NM_004793

1

NM_006335

1

X74606

Homo sapiens translocase of inner mitochondrial membrane 17 (yeast) homolog A (TIM17), mRNA

2.0

down

mitochondrial translocation

0.017267625

H.sapiens XAP-1 mRNA

1.6

down

biological process unknown

0.014891916

1

AK000689

Homo sapiens cDNA FLJ20682 fis, clone KAIA3543, highly similar to AF131826 H.sapiens clone 24945 mRNA

1.7

up

transcription

0.035494872

1

AK021789

Homo sapiens cDNA FLJ11727 fis, clone HEMBA1005374

2.3

up

biological process unknown

0.021014007

1

AK021815

Homo sapiens cDNA FLJ11753 fis, clone HEMBA1005583

1.6

up

glycogen biosynthesis

0.029970463

1

AK026764

Homo sapiens cDNA: FLJ23111 fis, clone LNG07835

2.2

up

biological process unknown

0.017174109

1

NM_002319

Homo sapiens leucine-rich neuronal protein (LRN) mRNA, complete sequence

2.1

up

biological process unknown

0.036158241

1

NM_006145

Homo sapiens heat shock 40kD protein 1 (HSPF1) mRNA

1.8

up

protein folding

0.024477331

1

X98115

H.sapiens mRNA for cardiac titin, clone ZisL

2.2

up

cytoskeletal anchoring

0.014638631

2

AB031038

Homo sapiens mRNA for hTbr2, complete cds

2.2

down

embryogenesis / morphogenesis

0.046379407

2

AF086452

Homo sapiens full length insert cDNA clone ZD83B06

2.6

down

biological process unknown

0.017967876
0.046664747

2

AK023814

Homo sapiens cDNA FLJ13752 fis, clone PLACE3000352

1.6

down

biological process unknown

2

NM_001486

Homo sapiens glucokinase (hexokinase 4) regulatory protein (GCKR) mRNA

1.8

down

nitrogen metabolism

0.012285037

2

NM_005691

Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 9 (ABCC9), mRNA

1.9

down

biological process unknown

0.014468696
0.014177713

2

NM_006033

Homo sapiens lipase, endothelial (LIPG), mRNA

1.5

down

lipid metabolism

2

NM_013356

Homo sapiens monocarboxylate transporter 3 (SLC16A8), mRNA

1.6

down

transport

0.049486595

2

NM_014632

Homo sapiens KIAA0750 gene product (KIAA0750), mRNA

3.4

down

cell motility

0.010994883

2

NM_018366

2

AF009290

Homo sapiens hypothetical protein FLJ11230 (FLJ11230), mRNA

1.6

down

biological process unknown

0.014768323

Homo sapiens clone HEC5 Cri-du-chat region mRNA

1.3

up

biological process unknown

0.029964519

2

AF097645

Homo sapiens candidate tumor suppressor protein DICE1 mRNA, complete cds

1.5

up

cell growth and/or maintenance

0.011826773

2

AK026339

Homo sapiens cDNA: FLJ22686 fis, clone HSI10987

1.5

up

cytoskeleton organization / biogenesis

0.011832297

2

AL050125

Homo sapiens mRNA; cDNA DKFZp586F071 (from clone DKFZp586F071)

1.6

up

biological process unknown

0.048827711

2

AL353951

Homo sapiens mRNA; cDNA DKFZp761A0423 (from clone DKFZp761A0423)

1.2

up

biological process unknown

0.020453577
0.02396184

2

M33197

Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, complete cds

1.6

up

biological process unknown

2

NM_003948

Homo sapiens cyclin-dependent kinase-like 2 (CDC2-related kinase) (CDKL2), mRNA

1.8

up

biological process unknown

2

NM_004293

Homo sapiens guanine deaminase (GDA), mRNA

1.7

up

nucleic acid metabolism

0.029360338

2

NM_006249

Homo sapiens proline-rich protein BstNI subfamily 3 (PRB3), mRNA

1.7

up

cytoskeleton organization / biogenesis

0.015708017

2

NM_006268

Homo sapiens requiem, apoptosis response zinc finger gene (REQ) mRNA

1.4

up

transcription regulation

0.032503592

2

NM_014684

Homo sapiens KIAA0373 gene product (KIAA0373), mRNA

1.8

up

muscle contraction

0.042243882

2

NM_016098

Homo sapiens HSPC040 protein (LOC51660), mRNA

1.5

up

porphyrin biosynthesis

0.016111001

2

NM_016616

Homo sapiens NM23-H8 (LOC51314), mRNA

1.7

up

nucleic acid metabolism

0.024200036

0.0294794

3

AF056418

Homo sapiens clone FBA4 Cri-du-chat critical region mRNA

1.5

down

biological process unknown

0.031744664

3

AF131745

Homo sapiens clone 25110 mRNA sequence

1.9

down

ubiquinone biosynthesis

0.013476411

3

AF147315

Homo sapiens full length insert cDNA clone YA85A01

1.3

down

biological process unknown

0.010894018

3

AK021970

Homo sapiens cDNA FLJ11908 fis, clone HEMBB1000089

2.0

down

biological process unknown

0.041219865

3

L07033

Human hydroxymethylglutaryl-CoA lyase mRNA, complete cds

1.7

down

leucine metabolism

0.037290172

3

NM_000329

Homo sapiens retinal pigment epithelium-specific protein (65kD) (RPE65) mRNA

1.5

down

vision

0.044554398

3

NM_004045

Homo sapiens ATX1 (antioxidant protein 1, yeast) homolog 1 (ATOX1), mRNA

1.5

down

copper ion transport

0.014124624

3

NM_014425

Homo sapiens inversin (INVS), mRNA

1.8

down

vesicle transport

0.027775891

3

NM_015044

Homo sapiens KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2, mRNA

1.5

down

intracellular protein traffic

0.032004408

3

NM_018077

Homo sapiens hypothetical protein FLJ10377 (FLJ10377), mRNA

1.4

down

RNA processing

0.012490038
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Homo sapiens hypothetical protein FLJ10563 (FLJ10563), mRNA

1.8

down

biological process unknown

0.042805641

Homo sapiens mRNA for KIAA1616 protein, partial cds

1.4

up

cell growth and/or maintenance

0.014551636

M37190

Human ras inhibitor mRNA, 3' end

1.5

up

cell growth and/or maintenance

0.021971274

3

X66087

H.sapiens a-myb mRNA

1.6

up

transcription regulation

0.017827478

4

AK000257

Homo sapiens cDNA FLJ20250 fis, clone COLF6635

1.6

down

biological process unknown

0.023477455

4

AL117636

Homo sapiens mRNA; cDNA DKFZp434H205 (from clone DKFZp434H205)

1.4

down

biological process unknown

0.013849179

3

NM_018139

3

AB046836

3

4

AL359559

Homo sapiens mRNA; cDNA DKFZp762O2215 (from clone DKFZp762O2215)

1.6

down

biological process unknown

0.012576309

4

AL390145

Homo sapiens mRNA; cDNA DKFZp762C115 (from clone DKFZp762C115)

1.6

down

biological process unknown

0.047102089

4

NM_020154

Homo sapiens chromosome 11 hypothetical protein ORF3 (LOC56851), mRNA

1.7

down

cell motility

0.040716234

4

X97303

H.sapiens mRNA for Ptg-12 protein

2.1

down

transcription regulation

0.026556997
0.014081919

4

AF085932

Homo sapiens full length insert cDNA clone YR56G07

1.6

up

biological process unknown

4

NM_004590

Homo sapiens small inducible cytokine subfamily A (Cys-Cys), member 16 (SCYA16), mRNA

1.5

up

immune response

0.011291698

4

NM_018247

Homo sapiens hypothetical protein FLJ10856 (FLJ10856), mRNA

1.5

up

mitochondrial processing

0.024924348

5

AF085899

Homo sapiens full length insert cDNA clone YQ15A02

1.6

down

biological process unknown

0.027363645

5

AF104921

Homo sapiens succinyl-CoA synthetase alpha subunit (SUCLA1) mRNA, complete cds

2.1

down

succinyl-CoA metabolism

0.028777168
0.031533837

5

AK000903

Homo sapiens cDNA FLJ10041 fis, clone HEMBA1001022

1.6

down

biological process unknown

5

NM_001151

Homo sapiens solute carrier family 25, member 4 (SLC25A4), nuclear gene encoding mitochondrial protein, mRNA

2.4

down

energy pathways

0.035615153

5

NM_012409

Homo sapiens prion gene complex, downstream (PRND), mRNA

1.9

down

biological process unknown

0.033394452

5

NM_012447

Homo sapiens stromal antigen 3 (STAG3), mRNA

1.8

down

male meiosis sister chromatid cohesion

0.029586542

5

NM_016497

Homo sapiens hypothetical protein (LOC51258), mRNA

1.9

down

biological process unknown

0.04049059

5

AK022226

Homo sapiens cDNA FLJ12164 fis, clone MAMMA1000605

2.5

up

biological process unknown

0.036196808
0.010343509

5

AL080113

Homo sapiens mRNA; cDNA DKFZp586K2322 (from clone DKFZp586K2322)

1.7

up

biological process unknown

5

NM_004887

Homo sapiens CXC chemokine in breast and kidney (BRAK) mRNA

1.5

up

immune response

0.011983042

5

NM_014012

Homo sapiens REM protein (REM), mRNA

1.2

up

cell surface receptor signal transduction

0.035096741

5

NM_014827

Homo sapiens KIAA0663 gene product (KIAA0663), mRNA

1.8

up

cytoskeleton organization / biogenesis

0.013963907

Appendix A.4 Microarray low laser hit list (p < 0.05). By microarray analysis, 72 genes were up- or downregulated
after a HF/LCD. Of those 72, 7 are known to be involved in glucose metabolism.
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Official Gene
Symbol

Common
Gene Name

Accession
number

Forward primer

Probe

Reverse primer

PPARGC1A
ND1
genomicLPL
CD36
LPL
FAS
PCK1
SCD
ACADM
PPARA
PLIN
SORBS1
PNPLA2
LIPE
PPARG
PPARG
CD68
CD163
CCL2
CCL3
RPS18

PGC1α

NM_0013261
AF346985
NC_000008
NM_000072
NM_000237
NM_000043
NM_002591
NM_005063
NM_000016
NM_001001928
NM_002666
NM_001034954
NM_020376
NM_005357
NM_005037
NM_015869
NM_001040059
NM_004244
NM_002982
NM_002983
NM_022551

AGGTGAAAGTGTAATACTGTTGGTTGA
CCCTAAAACCCGCCACATCT
CGAGTCGTCTTTCTCCTGATGAT
AGTCACTGCGACATGATTAATGGT
TATCCGCGTGATTGCAGAGA
TATGCTTCTTCGTGCAGCAGTT
CAGGCGGCTGAAGAAGTATGA
TGGCATTCCAGAATGATGTCTATG
TGCCCTGGAAAGGAAAACTTT
GCTTTGGCTTTACGGAATACCA
CACCGTGGCCATGTGGAT
CAAATTCCCTGAACTTCCTGAAA
CCACGGCGCTGGTCA
GACTTCCTCCGGGAGTATGTC
GTCAAACGAGAGTCAGCCTTTAACG
GATACACTGTCTGCAAACATATCACAA
GCTTCTCTCATTCCCCTATGGA
TGCAGAAAACCCCACAAAAAG
GATCTCAGTGCAGAGGCTCG
ACAGAATTTCATAGCTGACTACTTTGAGA
CGCCGCTAGAGGTGAAATTC

TGCTGAAGAGGGAAAGTGAGCGATTAGTTGA
CCATCACCCTCTACATCACCGCCC
ACATTCACCAGAGGGTC
CAGATGCAGCCTCATTTCCACCTTTTG
CTAGCTGGTCCACATCTCCAAGTCCT
AGCGCCTCCAGCACCCTGTTGT
AACTGCTGGTTGGCTCTCACTGACCC
CGTGACCACCGTGCCCACCACA
TGTAGAGCACCAAGCAATATCATTTATG
AGCCATCTGAGCCAGGACAGCTTCCTAA
CCCCTGAGCAGCCTGGCCC
CCAGCAAACTTCCGAAGAGGACAATCC
TTGGCACCAGCCTCACCCAGG
TGCATAAGGGATGCTTCTATGGCC
AGAGATGCCATTCTGGCCCACCAACTT
AGAGATGCCATTCTGGCCCACCAACTT
CAGCTTTGGATTCATGCAGGACCTCC
CACAACAGGTCGCTCATCCCGTCA
AGCTATAGAAGAATCACCAGCAGCAAGTGTCCC
AGTGCTCCAAGCCCGGTGTCATCTTC
ACCGGCGCAAGACGGACCAGA

CATGTAGAATTGGCAGGTGGAA
GAGCGATGGTGAGAGCTAAGGT
TTCTGGATTCCAATGCTTCGA
CTGCAATACCTGGCTTTTCTC
AGAGAGTCGATGAAGAGATGAATGG
GCTGCCACACGCTCCTCTAG
AACCGTCTTGCTTTCGATCCT
GGAATTATGAGGATCAGCATGTGT
GTTCAACTTTCATTGCCATTTCAG
TGAAAGCGTGTCCGTGATGA
GCCTGCATGGCCACTGAG
AGGAAACTGGTAGGTGGGAGTGTA
GGGCCTCTTTAGATACCTCAATGA
GCGTGAACTGGAAGCCCA
CCACGGAGCTGATCCCAA
CCACGGAGCTGATCCCAA
ATGTAGCTCAGGTAGACAACCTTCTG
CAAGGATCCCGACTGCAATAA
AATGGTCTTGAAGATCACAGCTTCT
GCCGGCTTCGCTTGGT
CATTCTTGGCAAATGCTTTCG

mtDNA
CD36
LPL
FAS
PCK1
SCD1
MCAD
PPARα
perilipin
CAP
ATGL
HSL
PPARγ1
PPARγ2
CD68
MAC-2
MCP-1
MIP-1α
18S

Appendix A.5 Oligonucleotide sequences for primer/probe sets used for qRT-PCR. PGC1α, peroxisome proliferative activated receptor,
gamma, coactivator 1, alpha; ND1, NADH dehydrogenase, subunit 1; genomicLPL, genomic lipoprotein lipase; CD36, CD36 molecule
(thrombospondin receptor); LPL, lipoprotein lipase; FAS, fatty acid synthase; PCK1, phosphoenolpyruvate carboxykinase 1; SCD1,
stearoyl-CoA desaturase; MCAD, acyl-Coenzyme A dehydrogenase C-4 to C-12 straight chain; PPARα, peroxisome proliferative activated
receptor, alpha; perilipin, lipid droplet associated protein; CAP, cbl-associated protein; ATGL, adipose triglyceride lipase; HSL, hormonesensitive lipase; PPARγ1, peroxisome proliferative activated receptor, gamma 1; PPARγ2, peroxisome proliferative activated receptor, gamma 2;
CD68, CD68 antigen; MAC-2, macrophage-associated antigen; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory
protein 1, alpha subunit;18S, ribosomal protein S18. For all assays performed using Taqman primers and probe, 18S was used as the internal
control.

108

APPENDIX B: PERMISSION TO REPRINT

B.1 Diabetes Permission to Reprint
Thank you for your request to use our material. Please see attached letter granting permisssion. Please contact me if you
have any questions.
Christine Taylor
Associate
Rights & Permissions
Publications
American Diabetes Association
Tel: 703-549-1500 ext 1635
Fax: 703-683-2890
Permissions@diabetes.org

>>> "Lauren Sparks" (by way of DIABETES Journal <diabetes@mail.med.upenn.edu>) <SparksLM@pbrc.edu> 8/9/2006
12:31:47 PM >>>
To whom it may concern:
I would like to request permission to reprint a paper published in Diabetes
(Vol 54: 1926-1933), on which I am the principal author, in my doctoral
dissertation. Your prompt attention would be greatly appreciated as the
deadline for the dissertation submission is September 27, 2006.
Sincerely,
Lauren Sparks
Lauren M Sparks ("Sparky")
Graduate Assistant
Pennington Biomedical Research Center
6400 Perkins Road
Baton Rouge, LA
70808
225.763.2726 (office)
225.763.3026 (lab)

November 13, 2006
Lauren Sparks
Pennington Biomedical Research Center
6400 Perkins Road
Baton Rouge, LA 70808
Permission Request Number: CT080906-PBRC
Dear Ms. Sparks:

We are pleased to grant permission to you to reproduce the following article:
9 A High-Fat Diet Coordinately Downregulates Genes Required for Mitochondrial
Oxidative Phosphorylation in Skeletal Muscle
From: Diabetes, Vol. 54, 2005; 1926-1933
For use in: Thesis

109

This permission is a one-time, non-exclusive grant for English language use, for print usage
only. No permission is granted for any other uses, including electronic ones.
No fee will be required, but please make acknowledgments to the author and work. Our material
that you reproduce or distribute must bear the following copyright notice:
“Copyright © 2005 American Diabetes Association
From Diabetes, Vol. 54, 2005; 1926-1933
Reprinted with permission from The American

Diabetes

Association.”

Sincerely,

Christine N. Taylor

Unless specifically noted here, the permission granted does not include the use of the
American Diabetes Association logo or the cover logo of the journal(s) from which the
material originates. Permission to reproduce material from the journal(s) does not
constitute an agreement that the company making the request or the company
sponsoring the resulting product may act as an agent of the American Diabetes
Association or of the journal(s).

110

B.2 Metabolism: Clinical and Experimental Permission to Reprint
Dear Lauren M Sparks
We hereby grant you permission to reproduce the material detailed below at
no charge in your thesis subject to the following conditions:
1.
If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another
source, permission must also be sought from that source. If such permission
is not obtained then that material may not be included in your
publication/copies.
2.
Suitable acknowledgment to the source must be made, either as a
footnote or in a reference list at the end of your publication, as follows:
"Reprinted from Publication title, Vol number, Author(s),
Title of article, Pages No., Copyright (Year), with permission from
Elsevier".
3.
Reproduction of this material is confined to the purpose for which
permission is hereby given.
4.
This permission is granted for non-exclusive world English rights
only. For other languages please reapply separately for each one required.
Permission excludes use in an electronic form. Should you have a specific
electronic project in mind please reapply for permission.
5.
This includes permission for UMI to supply single copies, on demand,
of the complete thesis. Should your thesis be published commercially,
please reapply for permission.
Yours sincerely
Jennifer Jones
Rights Assistant
Your future requests will be handled more quickly if you complete the online
form at www.elsevier.com/permissions <http://www.elsevier.com/permissions>
-----Original Message----From: Lauren Sparks [mailto:SparksLM@pbrc.edu]
Sent: 18 August 2006 16:33
To: Permissions@elsevier.com
Subject: YMETA_51057
To whom it may concern:
I would like to request permission to reprint a paper soon to be
published in Metabolism (YMETA_51057), on which I am the principal author, in my
doctoral dissertation. Your prompt attention would be greatly appreciated
as the deadline for the dissertation submission is September 27, 2006.
Sincerely,
Lauren Sparks
Lauren M Sparks ("Sparky")
Graduate Assistant
Pennington Biomedical Research Center
6400 Perkins Road
Baton Rouge, LA
70808
225.763.2726 (office)
225.763.3026 (lab)

111

VITA
Lauren Marie Sparks was born on June 1, 1979, in Baton Rouge, Louisiana. She
then moved to Patterson, Louisiana, where she attended elementary school, junior high
school and high school. In August of 1997, she moved to Baton Rouge, Louisiana, to
attend college at Louisiana State University where she received a Bachelor of Science in
zoology in May 2002 and a Bachelor of Arts in Spanish in August 2002. She continued
her graduate education at Louisiana State University in the Department of Biological
Sciences, where she earned a Doctor of Philosophy degree in biological sciences in
December 2006, while working in the laboratory of Dr. Steven R. Smith at Pennington
Biomedical Research Center. The title of her doctoral dissertation was “Substrate
Utilization in Skeletal Muscle and Adipose Tissue”. She will continue her scientific
career as a post-doctoral researcher with Dr. David E. Kelley at the University of
Pittsburgh Medical Center, Montefiore Hospital.

112

